<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Beta‐blockers for preventing aortic dissection in Marfan syndrome - Koo, HK - 2017 | Cochrane Library</title> <meta content="Beta‐blockers for preventing aortic dissection in Marfan syndrome - Koo, HK - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011103.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Beta‐blockers for preventing aortic dissection in Marfan syndrome - Koo, HK - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011103.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011103.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Beta‐blockers for preventing aortic dissection in Marfan syndrome" name="citation_title"/> <meta content="Hyun‐Kyoung Koo" name="citation_author"/> <meta content="University of British Columbia" name="citation_author_institution"/> <meta content="hkkoo@alumni.ubc.ca" name="citation_author_email"/> <meta content="Kendra AK Lawrence" name="citation_author"/> <meta content="University of Utah" name="citation_author_institution"/> <meta content="Vijaya M Musini" name="citation_author"/> <meta content="University of British Columbia" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD011103.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/11/07" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011103.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011103.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011103.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenergic beta‐Antagonists [*therapeutic use]; Aortic Dissection [etiology, mortality, *prevention &amp; control]; Marfan Syndrome [*complications]; Propranolol [*therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011103.pub2&amp;doi=10.1002/14651858.CD011103.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011103.pub2&amp;doi=10.1002/14651858.CD011103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011103.pub2&amp;doi=10.1002/14651858.CD011103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011103.pub2&amp;doi=10.1002/14651858.CD011103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011103.pub2&amp;doi=10.1002/14651858.CD011103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011103.pub2&amp;doi=10.1002/14651858.CD011103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011103.pub2&amp;doi=10.1002/14651858.CD011103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011103.pub2&amp;doi=10.1002/14651858.CD011103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011103.pub2&amp;doi=10.1002/14651858.CD011103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011103.pub2&amp;doi=10.1002/14651858.CD011103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011103.pub2&amp;doi=10.1002/14651858.CD011103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011103.pub2&amp;doi=10.1002/14651858.CD011103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011103.pub2&amp;doi=10.1002/14651858.CD011103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011103.pub2&amp;doi=10.1002/14651858.CD011103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011103.pub2&amp;doi=10.1002/14651858.CD011103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011103.pub2&amp;doi=10.1002/14651858.CD011103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011103.pub2&amp;doi=10.1002/14651858.CD011103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011103.pub2&amp;doi=10.1002/14651858.CD011103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011103.pub2&amp;doi=10.1002/14651858.CD011103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011103.pub2&amp;doi=10.1002/14651858.CD011103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011103.pub2&amp;doi=10.1002/14651858.CD011103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011103.pub2&amp;doi=10.1002/14651858.CD011103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011103.pub2&amp;doi=10.1002/14651858.CD011103.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="4nUWI3Cc";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011103\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011103\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011103\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011103\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","pl","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011103.pub2",title:"Beta\\u2010blockers for preventing aortic dissection in Marfan syndrome",firstPublishedDate:"Nov 7, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Heart Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=4nUWI3Cc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011103.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011103.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011103.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011103.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011103.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011103.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011103.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011103.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011103.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011103.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4521 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011103.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011103.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011103.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011103.pub2/full#CD011103-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011103.pub2/full#CD011103-sec-0083"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011103.pub2/full#CD011103-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011103.pub2/full#CD011103-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011103.pub2/full#CD011103-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011103.pub2/full#CD011103-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011103.pub2/full#CD011103-sec-0052"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011103.pub2/full#CD011103-sec-0068"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011103.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011103.pub2/appendices#CD011103-sec-0088"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011103.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011103.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/table_n/CD011103StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/table_n/CD011103StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011103.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011103.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011103.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011103.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011103.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011103.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Beta‐blockers for preventing aortic dissection in Marfan syndrome</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011103.pub2/information#CD011103-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Hyun‐Kyoung Koo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011103.pub2/information#CD011103-cr-0003">Kendra AK Lawrence</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011103.pub2/information#CD011103-cr-0004">Vijaya M Musini</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/information/en#CD011103-sec-0092">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 07 November 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011103.pub2">https://doi.org/10.1002/14651858.CD011103.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011103-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011103-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011103-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011103-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011103-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011103-abs-0001" lang="en"> <section id="CD011103-sec-0001"> <h3 class="title" id="CD011103-sec-0001">Background</h3> <p>Marfan syndrome is a hereditary disorder affecting the connective tissue and is caused by a mutation of the fibrillin‐1 (FBN1) gene. It affects multiple systems of the body, most notably the cardiovascular, ocular, skeletal, dural and pulmonary systems. Aortic root dilatation is the most frequent cardiovascular manifestation and its complications, including aortic regurgitation, dissection and rupture are the main cause of morbidity and mortality. </p> </section> <section id="CD011103-sec-0002"> <h3 class="title" id="CD011103-sec-0002">Objectives</h3> <p>To assess the long‐term efficacy and safety of beta‐blocker therapy as compared to placebo, no treatment or surveillance only in people with Marfan syndrome. </p> </section> <section id="CD011103-sec-0003"> <h3 class="title" id="CD011103-sec-0003">Search methods</h3> <p>We searched the following databases on 28 June 2017; CENTRAL, MEDLINE, Embase, Science Citation Index Expanded and the Conference Proceeding Citation Index ‐ Science in the Web of Science Core Collection. We also searched the Online Metabolic and Molecular Bases of Inherited Disease (OMMBID), ClinicalTrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) on 30 June 2017. We did not impose any restriction on language of publication. </p> </section> <section id="CD011103-sec-0004"> <h3 class="title" id="CD011103-sec-0004">Selection criteria</h3> <p>All randomised controlled trials (RCTs) of at least one year in duration assessing the effects of beta‐blocker monotherapy compared with placebo, no treatment or surveillance only, in people of all ages with a confirmed diagnosis of Marfan syndrome were eligible for inclusion. </p> </section> <section id="CD011103-sec-0005"> <h3 class="title" id="CD011103-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened titles and abstracts for inclusion, extracted data and assessed trial quality. Trial authors were contacted to obtain missing data. Dichotomous outcomes will be reported as relative risk and continuous outcomes as mean differences with 95% confidence intervals. We assessed the quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. </p> </section> <section id="CD011103-sec-0006"> <h3 class="title" id="CD011103-sec-0006">Main results</h3> <p>One open‐label, randomised, single‐centre trial including 70 participants with Marfan syndrome (aged 12 to 50 years old) met the inclusion criteria. Participants were randomly assigned to propranolol (N = 32) or no treatment (N = 38) for an average duration of 9.3 years in the control group and 10.7 years in the treatment group. The initial dose of propranolol was 10 mg four times daily and the optimal dose was reached when the heart rate remained below 100 beats per minute during exercise or the systolic time interval increased by 30%. The mean (± standard error (SE)) optimal dose of propranolol was 212 ± 68 mg given in four divided doses daily. </p> <p>Beta‐blocker therapy did not reduce the incidence of all‐cause mortality (RR 0.24, 95% CI 0.01 to 4.75; participants = 70; low‐quality evidence). Mortality attributed to Marfan syndrome was not reported. Non‐fatal serious adverse events were also not reported. However, study authors report on pre‐defined, non‐fatal clinical endpoints, which include aortic dissection, aortic regurgitation, cardiovascular surgery and congestive heart failure. Their analysis showed no difference between the treatment and control groups in these outcomes (RR 0.79, 95% CI 0.37 to 1.69; participants = 70; low‐quality evidence). </p> <p>Beta‐blocker therapy did not reduce the incidence of aortic dissection (RR 0.59, 95% CI 0.12 to 3.03), aortic regurgitation (RR 1.19, 95% CI 0.18 to 7.96), congestive heart failure (RR 1.19, 95% CI 0.18 to 7.96) or cardiovascular surgery, (RR 0.59, 95% CI 0.12 to 3.03); participants = 70; low‐quality evidence. </p> <p>The study reports a reduced rate of aortic dilatation measured by M‐mode echocardiography in the treatment group (aortic ratio mean slope: 0.084 (control) vs 0.023 (treatment), P &lt; 0.001). The change in systolic and diastolic blood pressure, total adverse events and withdrawal due to adverse events were not reported in the treatment or control group at study end point. </p> <p>We judged this study to be at high risk of selection (allocation concealment) bias, performance bias, detection bias, attrition bias and selective reporting bias. The overall quality of evidence was low. We do not know whether a statistically significant reduced rate of aortic dilatation translates into clinical benefit in terms of aortic dissection or mortality. </p> </section> <section id="CD011103-sec-0007"> <h3 class="title" id="CD011103-sec-0007">Authors' conclusions</h3> <p>Based on only one, low‐quality RCT comparing long‐term propranolol to no treatment in people with Marfan syndrome, we could draw no definitive conclusions for clinical practice. High‐quality, randomised trials are needed to evaluate the long‐term efficacy of beta‐blocker treatment in people with Marfan syndrome. Future trials should report on all clinically relevant end points and adverse events to evaluate benefit versus harm of therapy. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011103-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011103-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011103-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011103-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011103-abs-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD011103-abs-0005">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011103-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011103-abs-0003" lang="en"> <h3>Beta‐blocker treatment in Marfan syndrome</h3> <p><b>Question</b> <br/> Do the benefits of beta‐blocker therapy for Marfan syndrome outweigh the harms, as compared to placebo or no treatment? </p> <p><b>Background</b> <br/> Marfan syndrome is a hereditary disorder affecting multiple systems in the body. Enlargement of the aorta (the largest blood vessel that carries blood out of the heart) is one of the most common and important features of this disease. It can lead to life‐threatening problems, such as aortic dissection, which is a tear in the inner walls of the aorta causing blood to escape into the layers of the aortic wall, accumulate and potentially rupture. </p> <p>Beta‐blockers, a group of drugs used to decrease blood pressure, have been recommended by guidelines as the first line medical treatment of Marfan syndrome. The exact mechanism of action of beta‐blockers in Marfan syndrome is not known. </p> <p><b>Search Date</b> <br/> The evidence is current to June 2017. </p> <p><b>Study characteristics</b> <br/> We included one study of 70 participants aged 12 to 50 years old with Marfan syndrome, who were assigned to either a beta‐blocker called propranolol or no treatment for an average duration of 9.3 years in the control (no treatment) group and 10.7 years in the treatment group. </p> <p><b>Study funding source</b> <br/> This study was supported by grants from the National Institute of Health, the US Food and Drug Administration, and the National Marfan Foundation. </p> <p><b>Key results and conclusions</b> <br/> Propranolol compared to no treatment did not reduce mortality or morbidity, including aortic dissection, aortic regurgitation (leaking of the aortic valve causing reverse blood flow into the heart), heart failure (inability to pump enough blood around the body), and heart surgery. However, it reduced the rate of enlargement of the aortic diameter. Harms have not been fully reported in this study. We judged this trial to have high risk of bias and low‐quality evidence. This study provides inadequate evidence to inform people with Marfan syndrome, their families and care‐providers. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011103-sec-0083" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011103-sec-0083"></div> <h3 class="title" id="CD011103-sec-0084">Implications for practice</h3> <section id="CD011103-sec-0084"> <p>From the one randomised controlled trial (RCT) that met the inclusion criteria for this review, we found very low‐quality evidence that beta‐blockers decrease the rate of aortic dilatation in the adolescent and adult population with Marfan syndrome. This means that we have very little confidence in the effect estimate and it is likely to be substantially different from the true effect. We believe the evidence is too poor to inform patients on clinical outcomes. The decrease in aortic diameter did not lead to reduced mortality, and non‐fatal morbidity outcomes were not different between treatment and control groups. It is therefore difficult to know the clinical relevance of the small but statistically significant decreased rate of aortic root growth and whether the reduced rate of aortic dilatation confers benefit on prognosis. We therefore cannot make definitive conclusions on the efficacy of beta‐blocker treatment on overall and event‐free survival, quality of life or adverse effects of this potentially life‐long treatment. </p> </section> <h3 class="title" id="CD011103-sec-0085">Implications for research</h3> <section id="CD011103-sec-0085"> <p>This review has highlighted the limited evidence that supports the role of beta‐blockers as a gold‐standard, prophylactic treatment in people of all ages with Marfan’s syndrome. High‐quality RCTs are required to establish more robust recommendations. However, this will be challenging as it may be considered unethical to conduct a double‐blind, placebo study given that beta‐blockers have been demonstrated to reduce the rate of aortic dilatation and the potentially fatal nature of aortic dissection and other cardiovascular outcomes in Marfan’s syndrome. If such future trials were conducted, it would likely only be feasible with an open‐label control or if aortic dilatation was not present at study initiation – a subpopulation where the role of beta‐blocker treatment is even more controversial. Close surveillance and well‐defined clinical endpoints would be important in the study design. Furthermore, future studies will need to incorporate clinically relevant outcome measures, such as mortality, non‐fatal serious endpoints such as aortic dissection and cardiovascular surgery, quality of life and adverse events. Subanalyses according to age, sex, pregnancy, family history, genetic mutation, drug subtype and dosing would provide valuable insight. The effectiveness of other non‐pharmacological interventions such as lifestyle, exercise, frequency and type of surveillance also warrants further research. </p> <p>Given that beta‐blockers have now become the accepted norm in clinical practice and it is therefore unlikely that new studies with beta‐blocker monotherapy will be conducted in the future, we would like to expand the scope of this review in future updates and systematically review all available information including other study designs such as non‐randomised clinical trials and retrospective studies. </p> <p>Lastly, the focus of our review is on beta‐blocker monotherapy compared to no treatment or surveillance only. Further review on the comparison with other anti‐hypertensive medications and the role of combination therapy with beta‐blockers is required. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011103-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011103-sec-0022"></div> <div class="table" id="CD011103-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Beta‐blockers compared with placebo, no treatment or surveillance only for preventing aortic dissection in Marfan's syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Beta‐blockers compared with placebo, no treatment or surveillance only for preventing aortic dissection in Marfan syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: people with confirmed diagnosis of Marfan syndrome </p> <p><b>Settings</b>: outpatient </p> <p><b>Intervention</b>: beta‐blockers </p> <p><b>Comparison</b>: placebo or no treatment or surveillance only </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> <p><b>Follow‐up: mean 9.3 years in control group and 10.7 years in treatment group</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b> Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Risk with placebo, no treatment or surveillance only</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Risk with beta blockers</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> <p>(1 to 250)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.24</b> </p> <p>(0.01 to 4.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> L<b>ow<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinically important non‐fatal end point as defined by</b><a href="./references#CD011103-bbs2-0001" title="ShoresJ , BergerKR , MurphyEA , PyeritzRE . Progression of aortic dilatation and the benefit of long term beta‐adrenergic blockade in Marfan's syndrome. New England Journal of Medicine1994;330(9):1335‐41. ">Shores 1994</a><b>(</b>aortic dissection, aortic regurgitation, congestive heart failure, or cardiovascular surgery) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>316 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>249 per 1000</b> </p> <p>(117 to 534)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.79</b> </p> <p>(0.37 to 1.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> L<b>ow<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute aortic dissection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>105 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> <p>(13 to 319)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.59</b> </p> <p>(0.12 to 3.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> L<b>ow<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aortic regurgitation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b> </p> <p>(9 to 419)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19</b> </p> <p>(0.18 to 7.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> L<b>ow<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Congestive heart failure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b> </p> <p>(9 to 419)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19</b> </p> <p>(0.18 to 7.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> L<b>ow<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular surgery</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>105 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> <p>(13 to 319)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.59</b> </p> <p>(0.12 to 3.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> L<b>ow<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aortic root diameter &gt; 6 cm</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> </p> <p>(2 to 480)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19</b> </p> <p>(0.08 to 18.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> L<b>ow<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one step for risk of bias (high risk of selection, performance, detection, attrition and selective outcome reporting bias).<br/> <sup>2</sup>Downgraded one step for very serious imprecision (wide confidence interval with very low event rate). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011103-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011103-sec-0023"></div> <section id="CD011103-sec-0024"> <h3 class="title" id="CD011103-sec-0024">Description of the condition</h3> <p>Marfan syndrome is a hereditary disorder affecting the connective tissue and is caused by a mutation of the fibrillin‐1 (FBN1) gene. It was first discovered in 1896 by Professor Antoine‐Bernard Marfan, a French paediatrician (<a href="./references#CD011103-bbs2-0017" title="FrankenR , DenHartogAW , SinghM , PalsG , ZwindermanAH , GroeninkM , et al. Marfan syndrome: progress report. Progress in Pediatric Cardiology2012;34:9‐14. ">Franken 2012</a>; <a href="./references#CD011103-bbs2-0027" title="JudgeDP , DietzHC . Marfan's syndrome. Lancet2005;366:1965‐76. ">Judge 2005</a>; <a href="./references#CD011103-bbs2-0029" title='KoracevicG , SakacD , PavlovicM , IlicD , TomasevicM , KosticT . Should we prescribe "vasodilating" beta‐blockers in Marfan syndrome to prevent aortic aneurysm and dissection?. Vojnosanitetski Pregled. Military‐Medical and Pharmaceutical Review2012;69(2):195‐200. '>Koracevic 2012</a>). The condition is estimated to have an incidence of 1 in 2000 to 1 in 5000 individuals (<a href="./references#CD011103-bbs2-0014" title="DanyiP , ElefteriadesJA , JovinIS . Medical therapy of thoracic aortic aneurysms. Trends in Cardiovascular Medicine2012;22:180‐4. ">Danyi 2012</a>; <a href="./references#CD011103-bbs2-0017" title="FrankenR , DenHartogAW , SinghM , PalsG , ZwindermanAH , GroeninkM , et al. Marfan syndrome: progress report. Progress in Pediatric Cardiology2012;34:9‐14. ">Franken 2012</a>; <a href="./references#CD011103-bbs2-0062" title="VonKodolitschY , RobinsonPN . Marfan syndrome: an update of genetics, medical and surgical management. Heart (British Cardiac Society)2007;93(6):755‐60. ">Von Kodolitsch 2007</a>; <a href="./references#CD011103-bbs2-0063" title="WrightJM , ConnollyHM . Management of Marfan syndrome and related disorders. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA (Accessed 9 April 2014). ">Wright 2012</a>). </p> <p>Marfan syndrome affects multiple systems of the body, most notably the cardiovascular, ocular, skeletal, dural and pulmonary systems (<a href="./references#CD011103-bbs2-0012" title="CastellanoJM , KovacicJC , SanzJ , FusterV . Are we ignoring the dilated thoracic aorta?. Annals of the New York Academy of Sciences2012;1254:164‐74. ">Castellano 2012</a>; <a href="./references#CD011103-bbs2-0046" title="PyeritzRE . Marfan syndrome: 30 years of research equals 30 years of additional life expectancy. Heart (British Cardiac Society)2009;95(3):173‐5. ">Pyeritz 2009</a>). Aortic root dilatation is the most frequent cardiovascular manifestation (<a href="./references#CD011103-bbs2-0061" title="VonKodolitschY , RybczynskiM . Cardiovascular aspects of the Marfan syndrome: a systematic review. In: RobinsonPN , GodfreyM editor(s). Marfan Syndrome: a Primer for Clinicans and Scientists. Dordrecht, the Netherlands: Eurekah.com and Kluwer Academic/Plenum Publishers, 2004:45‐69. ">Von Kodolitsch 2004</a>), and its complications, including aortic regurgitation, dissection and rupture are the main cause of morbidity and mortality in people with this disease (<a href="./references#CD011103-bbs2-0011" title="CanadasV , VilacostaI , BrunaI , FusterV . Marfan syndrome. Part 2: treatment and management of patients. Nature Reviews. Cardiology2010;7(5):266‐76. ">Canadas 2010</a>; <a href="./references#CD011103-bbs2-0017" title="FrankenR , DenHartogAW , SinghM , PalsG , ZwindermanAH , GroeninkM , et al. Marfan syndrome: progress report. Progress in Pediatric Cardiology2012;34:9‐14. ">Franken 2012</a>). One long‐term survival study of Marfan syndrome in the early 1970s showed the mean age of death to be 32 years for people who did not receive aortic surgery (<a href="./references#CD011103-bbs2-0041" title="MurdochJL , WalkerBA , HalpernBL , KuzmaJW , McKusickVA . Life expectancy and causes of death in the Marfan syndrome. New England Journal of Medicine1972;286:804‐8. ">Murdoch 1972</a>). </p> <p>Although other cardiovascular features such as valvular disease, endocarditis, cardiomyopathy and arrhythmias exist in these people with Marfan syndrome (<a href="./references#CD011103-bbs2-0044" title="PyeritzRE . The Marfan syndrome. Annual Review of Medicine2000;51:481‐510. ">Pyeritz 2000</a>; <a href="./references#CD011103-bbs2-0061" title="VonKodolitschY , RybczynskiM . Cardiovascular aspects of the Marfan syndrome: a systematic review. In: RobinsonPN , GodfreyM editor(s). Marfan Syndrome: a Primer for Clinicans and Scientists. Dordrecht, the Netherlands: Eurekah.com and Kluwer Academic/Plenum Publishers, 2004:45‐69. ">Von Kodolitsch 2004</a>), dissection of the aorta has been, and remains, the most common cause of death (<a href="./references#CD011103-bbs2-0045" title="PyeritzRE . A small molecule for a large disease. New England Journal of Medicine2008;358:2829‐31. ">Pyeritz 2008</a>; <a href="./references#CD011103-bbs2-0055" title="SilvermanDI , BurtonKJ , GrayJ , BosnerMS , KouchoukosNT , RomanMJ , et al. Life expectancy in the Marfan syndrome. American Journal of Cardiology1995;75(2):157‐60. ">Silverman 1995</a>). Aortic wall weakness, aortic dilatation and arterial hypertension are the major mechanisms of dissection and rupture (<a href="./references#CD011103-bbs2-0061" title="VonKodolitschY , RybczynskiM . Cardiovascular aspects of the Marfan syndrome: a systematic review. In: RobinsonPN , GodfreyM editor(s). Marfan Syndrome: a Primer for Clinicans and Scientists. Dordrecht, the Netherlands: Eurekah.com and Kluwer Academic/Plenum Publishers, 2004:45‐69. ">Von Kodolitsch 2004</a>). Research has shown that a defect in the FBN1 glycoprotein, a major constituent of the extracellular matrix microfibrils (<a href="./references#CD011103-bbs2-0010" title="BuntonTE , BieryNJ , MyersL , GayraudB , RamirezF , DietzHC . Phenotypic alteration of vascular smooth muscle cells precedes elastolysis in a mouse model of Marfan syndrome. Circulation Research2001;88(1):37‐43. ">Bunton 2001</a>), leads to poor structural and functional integrity of the normal vessel wall by several potential mechanisms (<a href="./references#CD011103-bbs2-0013" title="DanyiP , ElefteriadesJA , JovinIS . Medical therapy of thoracic aortic aneurysms. Are we there yet?. Circulation2011;124:1469‐76. ">Danyi 2011</a>; <a href="./references#CD011103-bbs2-0027" title="JudgeDP , DietzHC . Marfan's syndrome. Lancet2005;366:1965‐76. ">Judge 2005</a>; <a href="./references#CD011103-bbs2-0062" title="VonKodolitschY , RobinsonPN . Marfan syndrome: an update of genetics, medical and surgical management. Heart (British Cardiac Society)2007;93(6):755‐60. ">Von Kodolitsch 2007</a>). The changes in the walls of the elastic arteries occur primarily in the medial layer and are associated with less distensibility and increased stiffness leading to consequent weakening and dilatation, beginning in the sinuses of the aortic root and extending to the proximal ascending aorta (<a href="./references#CD011103-bbs2-0044" title="PyeritzRE . The Marfan syndrome. Annual Review of Medicine2000;51:481‐510. ">Pyeritz 2000</a>; <a href="./references#CD011103-bbs2-0046" title="PyeritzRE . Marfan syndrome: 30 years of research equals 30 years of additional life expectancy. Heart (British Cardiac Society)2009;95(3):173‐5. ">Pyeritz 2009</a>). </p> <p>Aortic root pathology has hence become the most important target for improving survival in people with Marfan syndrome (<a href="./references#CD011103-bbs2-0060" title="VaidyanathanB . Role of beta‐blockers in Marfan's syndrome and bicuspid aortic valve: a time for re‐appraisal. Annals of Pediatric Cardiology2008;1:149‐52. ">Vaidyanathan 2008</a>). As a result of improved diagnosis, careful monitoring, lifestyle guidance, medical and especially surgical management of this disease, the life expectancy of people with Marfan syndrome has increased by at least 30 years (<a href="./references#CD011103-bbs2-0046" title="PyeritzRE . Marfan syndrome: 30 years of research equals 30 years of additional life expectancy. Heart (British Cardiac Society)2009;95(3):173‐5. ">Pyeritz 2009</a>; <a href="./references#CD011103-bbs2-0055" title="SilvermanDI , BurtonKJ , GrayJ , BosnerMS , KouchoukosNT , RomanMJ , et al. Life expectancy in the Marfan syndrome. American Journal of Cardiology1995;75(2):157‐60. ">Silverman 1995</a>). Although the benefits of prophylactic aortic surgery have been clearly demonstrated, the value of reducing aortic dilatation medically is unclear in the clinical setting to reduce morbidity and mortality. </p> </section> <section id="CD011103-sec-0025"> <h3 class="title" id="CD011103-sec-0025">Description of the intervention</h3> <p>The primary aim of pharmacological therapy for Marfan syndrome is to slow down the rate of aortic dilatation with the goal to delay or prevent complications and surgical interventions (<a href="./references#CD011103-bbs2-0017" title="FrankenR , DenHartogAW , SinghM , PalsG , ZwindermanAH , GroeninkM , et al. Marfan syndrome: progress report. Progress in Pediatric Cardiology2012;34:9‐14. ">Franken 2012</a>). The beta‐blockade strategy began in 1971 when Halpern and colleagues suggested that the reduction of the rate of increase in aortic pressure over time was an important additional factor to lowering blood pressure alone in decreasing haemodynamic stress on the proximal aorta (<a href="./references#CD011103-bbs2-0022" title="HalpernBL , CharF , MurdochJL , HortonWB , McKusickVA . A prospectus on the prevention of aortic rupture in the Marfan syndrome with data on survivorship without treatment. Johns Hopkins Medical Journal1971;129:123‐9. ">Halpern 1971</a>; <a href="./references#CD011103-bbs2-0028" title="KeaneMG , PyeritzRE . Medical management of Marfan syndrome. Circulation2008;117:2802‐13. ">Keane 2008</a>; <a href="./references#CD011103-bbs2-0036" title="McKusickVA . Historical introduction. The Marfan syndrome: from clinical delineation to mutational characterization, a semiautobiographic account. In: RobinsonPN , GodfreyM editor(s). Marfan Syndrome: a Primer for Clinicans and Scientists. Dordrecht, the Netherlands: Eurekah.com and Kluwer Academic/Plenum Publishers, 2004:1‐12. ">McKusick 2004</a>). Beta‐blockers became, and have remained, the standard preventive treatment since the mid‐1990s when one randomised controlled trial (RCT), <a href="./references#CD011103-bbs2-0001" title="ShoresJ , BergerKR , MurphyEA , PyeritzRE . Progression of aortic dilatation and the benefit of long term beta‐adrenergic blockade in Marfan's syndrome. New England Journal of Medicine1994;330(9):1335‐41. ">Shores 1994</a>, concluded that prophylactic beta‐adrenergic blockade with propranolol slowed the rate of aortic dilatation and reduced the development of aortic complications in people with Marfan syndrome. Subsequent studies have shown varying results on the efficacy of beta‐blockade therapy (<a href="./references#CD011103-bbs2-0032" title="LeggetME , UngerTA , O'SullivanCK , ZwinkTR , BennettRL , ByersPH , et al. Aortic root complications in Marfan's syndrome: identification of a lower risk group. Heart1996;75:389‐95. ">Legget 1996</a>; <a href="./references#CD011103-bbs2-0050" title="RiosAS , SilberEN , BavishiN , VargaP , BurtonBK , ClarkWA , et al. Effect of long‐term β‐blockade on aortic root compliance in patients with Marfan syndrome. American Heart Journal1999;137:1057‐61. ">Rios 1999</a>; <a href="./references#CD011103-bbs2-0058" title="TierneyESS , FeingoldB , PrintzBF , ParkSC , GrahamD , KleinmanCS , et al. Beta‐blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome. Journal of Pediatrics2007;150(1):77‐82. ">Tierney 2007</a>). Despite the lack of conclusive evidence, it has been recommended that people with Marfan syndrome and aortic aneurysm should be prescribed beta‐blockers to reduce the rate of dilatation unless contraindicated (<a href="./references#CD011103-bbs2-0009" title="BoodhwaniM , AndelfingerG , LeipsicJ , LindsayT , McMurtyMS , TherrienJ , et al. Canadian Cardiovascular Society position statement on the management of thoracic aortic disease. Canadian Journal of Cardiology2014;30:577‐89. ">Boodhwani 2014</a>; <a href="./references#CD011103-bbs2-0026" title="HiratzkaLF , BakrisGL , BeckmanJA , BersinRM , CarrVF , Casey JrDE , et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation2010;121:266‐369. ">Hiratzka 2010</a>; <a href="./references#CD011103-bbs2-0047" title="PyeritzRE . Evaluation of the adolescent or adult with some features of Marfan syndrome. Genetics in Medicine2012;14:171‐7. ">Pyeritz 2012</a>; <a href="./references#CD011103-bbs2-0063" title="WrightJM , ConnollyHM . Management of Marfan syndrome and related disorders. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA (Accessed 9 April 2014). ">Wright 2012</a>). Current beta‐blockers in use include propranolol, atenolol and metoprolol (<a href="./references#CD011103-bbs2-0063" title="WrightJM , ConnollyHM . Management of Marfan syndrome and related disorders. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA (Accessed 9 April 2014). ">Wright 2012</a>). Atenolol is currently the drug of choice as it has a longer half‐life and is more cardioselective than propranolol, with fewer side effects (<a href="./references#CD011103-bbs2-0028" title="KeaneMG , PyeritzRE . Medical management of Marfan syndrome. Circulation2008;117:2802‐13. ">Keane 2008</a>). The drug dosage is adjusted according to heart rate, aiming to maintain a rate of 60 to 70 beats per minute at rest and fewer than 100 beats per minute after sub‐maximal exercise (<a href="./references#CD011103-bbs2-0011" title="CanadasV , VilacostaI , BrunaI , FusterV . Marfan syndrome. Part 2: treatment and management of patients. Nature Reviews. Cardiology2010;7(5):266‐76. ">Canadas 2010</a>; <a href="./references#CD011103-bbs2-0034" title="LoeysBL , DietzHC , BravermanAC , CallewaertBL , DeBackerJ , DevereuxRB , et al. The revised Ghent nosology for the Marfan syndrome. Journal of Medical Genetics2010;47(7):476‐85. ">Loeys 2010</a>; <a href="./references#CD011103-bbs2-0063" title="WrightJM , ConnollyHM . Management of Marfan syndrome and related disorders. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA (Accessed 9 April 2014). ">Wright 2012</a>). Beta‐blockers have a significant side‐effect profile and documented adverse effects include bronchospasm, exercise intolerance, fatigue, depression, and first‐ and third‐degree heart block (<a href="./references#CD011103-bbs2-0019" title="GaoL , MaoQ , WenD , ZhangL , ZhouX , HuiR . The effect of beta‐blocker therapy on progressive aortic dilatation in children and adolescents with Marfan's syndrome: a meta‐analysis. Acta Paediatrica2011;100:101‐5. ">Gao 2011</a>; <a href="./references#CD011103-bbs2-0001" title="ShoresJ , BergerKR , MurphyEA , PyeritzRE . Progression of aortic dilatation and the benefit of long term beta‐adrenergic blockade in Marfan's syndrome. New England Journal of Medicine1994;330(9):1335‐41. ">Shores 1994</a>). </p> <p>Other anti‐hypertensive medications such as calcium channel blockers, angiotensin‐converting enzyme (ACE) inhibitors and, more recently, angiotensin receptor blockers (ARB) have been studied with mixed results (<a href="./references#CD011103-bbs2-0002" title="BhattAB , BuckJS , ZuflachtJP , MilianJ , KadivarS , GuavreauK , et al. Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome. Vascular Medicine2015;20:317‐25. ">Bhatt 2015</a>; <a href="./references#CD011103-bbs2-0004" title="LacroRV , DietzHC , SleeperLA , YetmanAT , BradleyTJ , ColanSD , et al. Atenolol versus losartan in children and young adults with Marfan's syndrome. New England Journal of Medicine2014;371:2061‐71. ">Lacro 2014</a>; <a href="./references#CD011103-bbs2-0037" title="MilleronO , ArnoultF , RopersJ , AegerterP , DetaintD , DelormeG , et al. Marfan Sartan: a randomized, double‐blind, placebo‐controlled trial. European Heart Journal2015;36:2160‐6. ">Milleron 2015</a>; <a href="./references#CD011103-bbs2-0051" title="Rossi‐FoulkesR , RomanMJ , RosenSE , Kramer‐FoxR , EhlersKH , O'LoughlinJE , et al. Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome. American Journal of Cardiology1999;83:1364‐68. ">Rossi‐Foulkes 1999</a>; <a href="./references#CD011103-bbs2-0059" title="TopouchianJ , BrisacAM , PannierB , VicautE , SafarM , AsmarR . Assessment of the acute arterial effects of converting enzyme inhibition in essential hypertension: a double‐blind comparative and crossover study. Journal of Human Hypertension1998;12:181‐7. ">Topouchian 1998</a>; <a href="./references#CD011103-bbs2-0006" title="WilliamsA , KennyD , WilsonD , FagenelloG , NelsonM , DunstanF , et al. Effects of atenolol, perindopril and verapamil on haemodynamic and vascular function in Marfan syndrome ‐ a randomised, double‐blind, crossover trial. European Journal of Clinical Investigation2012;42(8):891‐99. ">Williams 2012</a>; <a href="./references#CD011103-bbs2-0065" title="YetmanAT , BornemeierRA , McCrindleBW . Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. American Journal of Cardiology2005;95:1125‐7. ">Yetman 2005</a>). Several large RCTs assessing the effect of losartan (an angiotensin II type I receptor blocker) have recently been completed or are underway (<a href="./references#CD011103-bbs2-0003" title="FortezaA , EvangelistaA , SanchezV , Teixido‐TuraG , SanzP , GutierrezL , et al. Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial. European Heart Journal2016;37:978‐85. ">Forteza 2016</a>; <a href="./references#CD011103-bbs2-0018" title="GambarinF , FavalliV , SerioA , RegazziM , PasottiM , KlersyC , et al. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations. Journal of Cardiovascular Medicine2009;10(4):354‐62. ">Gambarin 2009</a>; <a href="./references#CD011103-bbs2-0004" title="LacroRV , DietzHC , SleeperLA , YetmanAT , BradleyTJ , ColanSD , et al. Atenolol versus losartan in children and young adults with Marfan's syndrome. New England Journal of Medicine2014;371:2061‐71. ">Lacro 2014</a>; <a href="./references#CD011103-bbs2-0040" title="MullenMJ , FlatherMD , JinXY , NewmanWG , ErdermG , GazeD , et al. A prospective, randomized, placebo‐controlled, double‐blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol. Trials2013;14:1‐14. ">Mullen 2013</a>; <a href="./references#CD011103-bbs2-0038" title="MobergK , DeNobeleS , DevosD , GoetghebeurE , SegersP , TrachetB . The Ghent Marfan Trial ‐ a randomized, double‐blind placebo controlled trial with losartan in Marfan patients treated with β‐blockers. International Journal of Cardiology2012;157:354‐8. ">Moberg 2012</a>). The use of an ACE inhibitor or an ARB is suggested for people who are unable to tolerate beta‐blockers or as an add‐on therapy if beta‐blockade monotherapy is unsuccessful at controlling blood pressure (<a href="./references#CD011103-bbs2-0028" title="KeaneMG , PyeritzRE . Medical management of Marfan syndrome. Circulation2008;117:2802‐13. ">Keane 2008</a>; <a href="./references#CD011103-bbs2-0048" title="PyeritzRE . What is the optimal medical therapy for Marfan syndrome?. Journal of Pediatrics2014;165:889‐90. ">Pyeritz 2014</a>; <a href="./references#CD011103-bbs2-0056" title="SinghMN , LacroRV . Recent clinical drug trials evidence in Marfan syndrome and clinical implications. Canadian Journal of Cardiology2016;32:66‐77. ">Singh 2016</a>; <a href="./references#CD011103-bbs2-0063" title="WrightJM , ConnollyHM . Management of Marfan syndrome and related disorders. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA (Accessed 9 April 2014). ">Wright 2012</a>). The Marfan Treatment Trialists' Collaboration has proposed a large, prospective, collaborative meta‐analysis of all the RCTs evaluating ARB treatment in Marfan syndrome (<a href="./references#CD011103-bbs2-0043" title="PitcherA , EmbersonJ , LacroRV , SleeperLA , StylianouM , MahonyL , et al. Design and rationale of a prospective, collaborative meta‐analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: a report from the Marfan Treatment Trialists’ Collaboration. American Heart Journal2015;169:605‐12. ">Pitcher 2015</a>). </p> </section> <section id="CD011103-sec-0026"> <h3 class="title" id="CD011103-sec-0026">How the intervention might work</h3> <p>Although the exact mechanism of beta‐blockers in Marfan syndrome is unknown, the potential benefits have been attributed to their negative inotropic and chronotropic effects, resulting in a reduction in aortic wall stress (<a href="./references#CD011103-bbs2-0011" title="CanadasV , VilacostaI , BrunaI , FusterV . Marfan syndrome. Part 2: treatment and management of patients. Nature Reviews. Cardiology2010;7(5):266‐76. ">Canadas 2010</a>). This is important in decreasing the progression of aortic dilatation as the degree of increase in aortic root diameter is a major indicator for the risk of dissection (<a href="./references#CD011103-bbs2-0027" title="JudgeDP , DietzHC . Marfan's syndrome. Lancet2005;366:1965‐76. ">Judge 2005</a>). The anti‐arrhythmic and anti‐fibrillatory effects of beta‐blockade are also believed to be advantageous as other cardiovascular manifestations such as mitral valve prolapse and left ventricular dilatation are common in Marfan syndrome, pre‐disposing people to arrhythmias (<a href="./references#CD011103-bbs2-0029" title='KoracevicG , SakacD , PavlovicM , IlicD , TomasevicM , KosticT . Should we prescribe "vasodilating" beta‐blockers in Marfan syndrome to prevent aortic aneurysm and dissection?. Vojnosanitetski Pregled. Military‐Medical and Pharmaceutical Review2012;69(2):195‐200. '>Koracevic 2012</a>). </p> <p>The cardiac cycle is pulsatile in nature, with aortic expansion during systole and recoil during diastole. This pulsatile flow can be characterised by a change in pressure over time and contributes to the progression of aortic dissection compared with non‐pulsatile flow (<a href="./references#CD011103-bbs2-0012" title="CastellanoJM , KovacicJC , SanzJ , FusterV . Are we ignoring the dilated thoracic aorta?. Annals of the New York Academy of Sciences2012;1254:164‐74. ">Castellano 2012</a>; <a href="./references#CD011103-bbs2-0033" title="LiaoSL , ElmariahS , Van derZeeS , SealoveBA , FusterV . Does medical therapy for thoracic aortic aneurysms really work? Are beta‐blockers truly indicated?. Cardiology Clinics2010;28:261‐9. ">Liao 2010</a>). The aorta buffers the level of fluctuation between the extreme pressures of systole and diastole, allowing a nearly continuous blood flow from the central to the peripheral vascular system (<a href="./references#CD011103-bbs2-0008" title="BelzGG . Elastic properties and Windkessel function of the human aorta. Cardiovascular Drugs and Therapy1995;9:73‐83. ">Belz 1995</a>; <a href="./references#CD011103-bbs2-0029" title='KoracevicG , SakacD , PavlovicM , IlicD , TomasevicM , KosticT . Should we prescribe "vasodilating" beta‐blockers in Marfan syndrome to prevent aortic aneurysm and dissection?. Vojnosanitetski Pregled. Military‐Medical and Pharmaceutical Review2012;69(2):195‐200. '>Koracevic 2012</a>). This protective function, known as the Windkessel effect, relies on the elasticity of the aorta (<a href="./references#CD011103-bbs2-0008" title="BelzGG . Elastic properties and Windkessel function of the human aorta. Cardiovascular Drugs and Therapy1995;9:73‐83. ">Belz 1995</a>), and, as Marfan syndrome is associated with abnormal aortic elastic properties (<a href="./references#CD011103-bbs2-0025" title="HirataK , TriposkiadisF , SparksE , BowenJ , WooleyCF , BoudoulasH . The Marfan syndrome: abnormal aortic elastic properties. Journal of the American College of Cardiology1991;181(1):57‐63. ">Hirata 1991</a>), people are therefore compromised. Studies have shown that beta‐blocker therapy may directly affect the aortic wall by increasing its distensibility, and decreasing aortic stiffness and pulse‐wave velocity (<a href="./references#CD011103-bbs2-0021" title="GroeninkM , DeRoosA , MulderBJM , SpaanJAE , Van derWallEE . Changes in aortic distensibility and pulse wave velocity assessed with magnetic resonance imaging following beta‐blocker therapy in the Marfan syndrome. American Journal of Cardiology1998;82:203‐8. ">Groenink 1998</a>; <a href="./references#CD011103-bbs2-0030" title="LadouceurM , FermanianC , LupoglazoffJM , EdouardT , DulacY , AcarP , et al. Effect of beta blockade on ascending aortic dilatation in children with the Marfan syndrome. American Journal of Cardiology2007;99:406‐9. ">Ladouceur 2007</a>; <a href="./references#CD011103-bbs2-0050" title="RiosAS , SilberEN , BavishiN , VargaP , BurtonBK , ClarkWA , et al. Effect of long‐term β‐blockade on aortic root compliance in patients with Marfan syndrome. American Heart Journal1999;137:1057‐61. ">Rios 1999</a>). With the favourable effects of beta‐blockers on change in pressure over time, this pharmacological intervention became important in the medical management in aortic dissection (<a href="./references#CD011103-bbs2-0012" title="CastellanoJM , KovacicJC , SanzJ , FusterV . Are we ignoring the dilated thoracic aorta?. Annals of the New York Academy of Sciences2012;1254:164‐74. ">Castellano 2012</a>; <a href="./references#CD011103-bbs2-0014" title="DanyiP , ElefteriadesJA , JovinIS . Medical therapy of thoracic aortic aneurysms. Trends in Cardiovascular Medicine2012;22:180‐4. ">Danyi 2012</a>; <a href="./references#CD011103-bbs2-0033" title="LiaoSL , ElmariahS , Van derZeeS , SealoveBA , FusterV . Does medical therapy for thoracic aortic aneurysms really work? Are beta‐blockers truly indicated?. Cardiology Clinics2010;28:261‐9. ">Liao 2010</a>). </p> </section> <section id="CD011103-sec-0027"> <h3 class="title" id="CD011103-sec-0027">Why it is important to do this review</h3> <p>Beta‐blockers have remained the standard treatment for the prevention of aortic complications since medical intervention was introduced in the 1970s. Studies investigating the efficacy and therapeutic benefit of beta‐blockade have produced heterogeneous and conflicting results, leading to much debate on their life‐long use for people with Marfan syndrome (<a href="./references#CD011103-bbs2-0030" title="LadouceurM , FermanianC , LupoglazoffJM , EdouardT , DulacY , AcarP , et al. Effect of beta blockade on ascending aortic dilatation in children with the Marfan syndrome. American Journal of Cardiology2007;99:406‐9. ">Ladouceur 2007</a>; <a href="./references#CD011103-bbs2-0058" title="TierneyESS , FeingoldB , PrintzBF , ParkSC , GrahamD , KleinmanCS , et al. Beta‐blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome. Journal of Pediatrics2007;150(1):77‐82. ">Tierney 2007</a>). One meta‐analysis, <a href="./references#CD011103-bbs2-0020" title="GersonyDR , McClaughlinMR , JinZ , GersonyWM . The effect of beta‐blocker therapy on clinical outcome in patients with Marfan's syndrome: a meta‐analysis. International Journal of Cardiology2007;114:303‐8. ">Gersony 2007</a>, included six studies, of which only one was an RCT, and concluded that there was no evidence that beta‐blocker therapy had clinical benefit in people with Marfan syndrome. Conversely, <a href="./references#CD011103-bbs2-0019" title="GaoL , MaoQ , WenD , ZhangL , ZhouX , HuiR . The effect of beta‐blocker therapy on progressive aortic dilatation in children and adolescents with Marfan's syndrome: a meta‐analysis. Acta Paediatrica2011;100:101‐5. ">Gao 2011</a> concluded from their meta‐analysis that routine prescription of beta‐blockers may offer substantial benefit on clinical end points for children and adolescents with Marfan syndrome. </p> <p>One Cochrane Review on the medical treatment for small abdominal aortic aneurysms (AAA) reported that there was no significant difference in AAA expansion or cardiovascular end points between beta‐blocker treatment and placebo. Furthermore, a significantly increased number of people discontinued beta‐blocker therapy for AAA management due to adverse effects and there was no significant difference in the combined overall mortality of the three included propranolol trials (<a href="./references#CD011103-bbs2-0052" title="RughaniG , RobertsonL , ClarkeM . Medical treatment for small abdominal aortic aneurysms. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD009536.pub2] ">Rughani 2012</a>). Although thoracic aortic aneurysms (TAA) are more common in Marfan syndrome and extrapolating data from AAA to TAA studies should be conducted with caution (<a href="./references#CD011103-bbs2-0012" title="CastellanoJM , KovacicJC , SanzJ , FusterV . Are we ignoring the dilated thoracic aorta?. Annals of the New York Academy of Sciences2012;1254:164‐74. ">Castellano 2012</a>), these findings do raise cause for concern. </p> <p>Lifelong treatment, as beta‐blockade therapy in Marfan syndrome currently remains, is not a decision or commitment that should be taken lightly. Even with the anticipation of other pharmacological treatments currently under trial, it is important to establish the efficacy of the baseline treatment that has been in place for decades. This would hopefully decrease the discrepancy gap between clinical practice and current evidence, and provide the physician with more options to optimise and individualise a management plan for his/her patient. Since aortic pathology is present in the vast majority of people with Marfan syndrome, and is the most life‐threatening manifestation of this disease (<a href="./references#CD011103-bbs2-0011" title="CanadasV , VilacostaI , BrunaI , FusterV . Marfan syndrome. Part 2: treatment and management of patients. Nature Reviews. Cardiology2010;7(5):266‐76. ">Canadas 2010</a>; <a href="./references#CD011103-bbs2-0017" title="FrankenR , DenHartogAW , SinghM , PalsG , ZwindermanAH , GroeninkM , et al. Marfan syndrome: progress report. Progress in Pediatric Cardiology2012;34:9‐14. ">Franken 2012</a>; <a href="./references#CD011103-bbs2-0019" title="GaoL , MaoQ , WenD , ZhangL , ZhouX , HuiR . The effect of beta‐blocker therapy on progressive aortic dilatation in children and adolescents with Marfan's syndrome: a meta‐analysis. Acta Paediatrica2011;100:101‐5. ">Gao 2011</a>; <a href="./references#CD011103-bbs2-0027" title="JudgeDP , DietzHC . Marfan's syndrome. Lancet2005;366:1965‐76. ">Judge 2005</a>), this review will focus on the effects of beta‐blockers for preventing aortic dissection in Marfan syndrome. Therefore, we will examine the most up‐to‐date literature to assess the long‐term efficacy of this treatment in people of all ages with Marfan syndrome and determine if current practice with life‐long beta‐blocker therapy is evidence‐based. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011103-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011103-sec-0028"></div> <p>To assess the long‐term efficacy and safety of beta‐blocker therapy as compared to placebo, no treatment or surveillance only in people with Marfan syndrome. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011103-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011103-sec-0029"></div> <section id="CD011103-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011103-sec-0031"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials (RCTs) of at least one year in duration assessing the effects of beta‐blocker monotherapy in people with Marfan syndrome were eligible for inclusion. </p> </section> <section id="CD011103-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included participants of all ages with a confirmed diagnosis of Marfan syndrome and excluded people with previous aortic root surgery, planned aortic surgery within one year of study enrolment, previous aortic dissection and co‐existing diagnoses of connective tissue disease. We also excluded pregnancy in people with Marfan syndrome. </p> </section> <section id="CD011103-sec-0033"> <h4 class="title">Types of interventions</h4> <p>We assessed beta‐blocker monotherapy compared with placebo, no treatment or surveillance only. </p> </section> <section id="CD011103-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD011103-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD011103-list-0001"> <li> <p>All‐cause mortality (including mortality attributed to Marfan syndrome)</p> </li> <li> <p>All non‐fatal serious adverse events (including all‐cause hospitalisations, cardiovascular events such as aortic dissection or rupture, and cardiovascular surgery) </p> </li> </ol> </p> </section> <section id="CD011103-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD011103-list-0002"> <li> <p>Measurements of the aortic root diameter taken by echocardiogram or other imaging modalities </p> </li> <li> <p>Systolic and diastolic blood pressure</p> </li> <li> <p>Total adverse events</p> </li> <li> <p>Withdrawals due to adverse events</p> </li> </ol> </p> </section> </section> </section> <section id="CD011103-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011103-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We identified trials through systematic searches of the following bibliographic databases on 28 June 2017: </p> <p> <ol id="CD011103-list-0003"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 5) in the Cochrane Library </p> </li> <li> <p>Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, MEDLINE Daily and MEDLINE (Ovid, 1946 to 28 June 2017) </p> </li> <li> <p>Embase (Ovid, 1980 to Week 26, 2017)</p> </li> <li> <p>Science Citation Index Expanded and the Conference Proceeding Citation Index ‐ Science, Web of Science Core Collection (Thomson Reuters, 1970 to 28 June 2017) </p> </li> </ol> </p> <p>We adapted the search strategy for MEDLINE (Ovid) (<a href="./appendices#CD011103-sec-0089">Appendix 1</a>) for use in the other databases. The Cochrane sensitivity‐maximising RCT filter was applied to MEDLINE (Ovid) (<a href="./references#CD011103-bbs2-0031" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Review of Interventions Version 5.1.0. (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Lefebvre 2011</a>) and an adaptation of it to Web of Science. For Embase, we applied RCT filter terms as recommended in the <i>Cochrane Handbook for Systematic Reviews of Intrventions</i> (<a href="./references#CD011103-bbs2-0031" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Review of Interventions Version 5.1.0. (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Lefebvre 2011</a>). Additionally, we applied an adverse events filter to MEDLINE and Embase (<a href="./references#CD011103-bbs2-0035" title="LokeYK , PriceD , HerxheimberA . Chapter 14: Adverse effects. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Loke 2011</a>). </p> <p>We also searched the Online Metabolic and Molecular Bases of Inherited Disease (OMMBID) and sought to identify ongoing, recently completed or unpublished trials by searching clinical trials registers; ClinicalTrials.gov (<a href="http://www.ClinicalTrials.gov" target="_blank">www.ClinicalTrials.gov</a>) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) Search Portal (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>), using the terms 'Marfan syndrome' or 'Marfan syndrome' (last updated search on 30 June 2017). </p> <p>We did not impose any restriction on language of publication.</p> </section> <section id="CD011103-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We examined reference lists of eligible studies and reviewed articles manually for additional references. We contacted the authors of the included study for missing data via email. </p> </section> </section> <section id="CD011103-sec-0040"> <h3 class="title" id="CD011103-sec-0040">Data collection and analysis</h3> <section id="CD011103-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Two review authors (HK and KL) independently reviewed the titles and abstracts of all potential studies identified by the search strategy outlined above. We initially screened studies and coded them as 'Yes', 'Maybe' or 'No'. We resolved discrepancies by consensus or discussion with the third review author (VM). </p> <p>For inclusion, a trial had to meet the following criteria:</p> <p> <ol id="CD011103-list-0004"> <li> <p>the study was a RCT;</p> </li> <li> <p>the study population had a diagnosis of Marfan syndrome;</p> </li> <li> <p>the intervention was beta‐blocker mono‐therapy compared with placebo, no treatment, or surveillance only; </p> </li> <li> <p>the study reported one or more primary or secondary outcome measures.</p> </li> </ol> </p> <p>We obtained full‐text versions of all potentially eligible studies and made a decision for inclusion or exclusion. Where there were any differences in opinion regarding the suitability of a study, we discussed these with the third review author (VM). We included detailed trial reports where methodology could be assessed. </p> </section> <section id="CD011103-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (HK and VM) independently extracted relevant data from the retrieved articles using a data extraction form (<a href="./appendices#CD011103-sec-0090">Appendix 2</a>). We resolved any disagreement in the data extraction and management by discussion. </p> </section> <section id="CD011103-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (HK and KL) independently assessed the risk of bias for the included study. We performed this assessment of methodological quality according to the criteria described in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of interventions</i> (<a href="./references#CD011103-bbs2-0024" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), and included the following: </p> <p> <ol id="CD011103-list-0005"> <li> <p>random sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants and personnel;</p> </li> <li> <p>blinding of outcome assessment;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting;</p> </li> <li> <p>other bias.</p> </li> </ol> </p> <p>Each domain was allocated as either 'low, high or unclear risk'. We resolved any disagreements by discussion with the third author (VM). </p> </section> <section id="CD011103-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>We summarised dichotomous data (all‐cause mortality, non‐fatal serious adverse events, total adverse events and withdrawal due to adverse events) using risk ratios (RR) with 95% confidence intervals (CI) where relevant and when data were available. We planned to use mean differences (MD) with 95% CI to summarise continuous outcomes (measurement of aortic diameter, systolic and diastolic blood pressure). </p> </section> <section id="CD011103-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>For dichotomous outcomes, the unit of analysis was the number of individuals assigned to beta‐blocker treatment and the number of individuals assigned to the control group. For continuous outcomes, we planned the unit of analysis was to be the mean, standard deviation, and the number of individuals in the treatment and control groups (<a href="./references#CD011103-bbs2-0016" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Deeks 2011</a>). </p> </section> <section id="CD011103-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>One trial, <a href="./references#CD011103-bbs2-0001" title="ShoresJ , BergerKR , MurphyEA , PyeritzRE . Progression of aortic dilatation and the benefit of long term beta‐adrenergic blockade in Marfan's syndrome. New England Journal of Medicine1994;330(9):1335‐41. ">Shores 1994</a> met the inclusion criteria. We used data available in the publication and also contacted the study authors via email for additional information regarding missing data. The study protocol was not available. This study is not registered with ClinicalTrials.gov. </p> </section> <section id="CD011103-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>As only one trial met the inclusion criteria, we could not perform heterogeneity assessments. If sufficient numbers of studies had been available, we would have performed a Chi<sup>2</sup> test to determine the presence of statistical heterogeneity at a significance level of P value less than 0.10. If more studies become available in the future, we will assess the quantity of heterogeneity using the I<sup>2</sup> statistic (<a href="./references#CD011103-bbs2-0023" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>) with the following parameters: </p> <p> <ol id="CD011103-list-0006"> <li> <p>I<sup>2</sup> = 0% to 40% heterogeneity may not be important; </p> </li> <li> <p>I<sup>2</sup> = 30% to 60% may represent moderate heterogeneity; </p> </li> <li> <p>I<sup>2</sup> = 50% to 90% may represent substantial heterogeneity; </p> </li> <li> <p>I<sup>2</sup> = 75% to 90% considerable heterogeneity. </p> </li> </ol> </p> </section> <section id="CD011103-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>If we identified at least 10 studies, we planned to assess reporting bias by reviewing the funnel plots and performing a linear regression test. As only a single study met the inclusion criteria we could not assess reporting bias. </p> </section> <section id="CD011103-sec-0049"> <h4 class="title">Data synthesis</h4> <p>We used the most recent version of the Cochrane Review Manager 5 software (RevMan 5) for data synthesis and analysis (<a href="./references#CD011103-bbs2-0049" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We utilised a fixed‐effect model and all data are accompanied by the 95% CI. </p> </section> <section id="CD011103-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>As only one study met the inclusion criteria, we did not perform subgroup analysis. If sufficient numbers of trials were available, we had planned to perform the following subgroup analyses: </p> <p> <ol id="CD011103-list-0007"> <li> <p>severity of disease at baseline: mild, moderate or severe;</p> </li> <li> <p>sex: female versus male;</p> </li> <li> <p>age groups: children/adolescents versus adults.</p> </li> </ol> </p> </section> <section id="CD011103-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>We did not perform sensitivity analysis as only one trial met the inclusion criteria. If sufficient numbers of trials were available, we had planned to assess the following features of methodological quality of included studies: sequence generation, allocation concealment, blinding of participants and assessors, and incomplete outcome data. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011103-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011103-sec-0052"></div> <section id="CD011103-sec-0053"> <h3 class="title">Description of studies</h3> <section id="CD011103-sec-0054"> <h4 class="title">Results of the search</h4> <p>We screened a total of 1819 references from databases, trials registers and handsearching after de‐duplication. We retrieved 15 full‐text articles for further assessment. Only one study fulfilled the eligibility criteria for inclusion (<a href="./references#CD011103-bbs2-0001" title="ShoresJ , BergerKR , MurphyEA , PyeritzRE . Progression of aortic dilatation and the benefit of long term beta‐adrenergic blockade in Marfan's syndrome. New England Journal of Medicine1994;330(9):1335‐41. ">Shores 1994</a>). See study flow diagram (<a href="./references#CD011103-bbs2-0039" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , the PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Medicine2009;6(7):e1000100. [DOI: 10.1371/journal.pmed.1000100] ">Moher 2009</a>) (<a href="#CD011103-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD011103-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD011103-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_n/nCD011103-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD011103-sec-0055"> <h4 class="title">Included studies</h4> <p>The one included study by <a href="./references#CD011103-bbs2-0001" title="ShoresJ , BergerKR , MurphyEA , PyeritzRE . Progression of aortic dilatation and the benefit of long term beta‐adrenergic blockade in Marfan's syndrome. New England Journal of Medicine1994;330(9):1335‐41. ">Shores 1994</a>, titled 'Progression of aortic dilatation and the benefit of long‐term β‐adrenergic blockade in Marfan syndrome' is an open‐label, randomised trial that included adolescent and adult participants with Marfan syndrome to receive either beta‐blocker (propranolol) or no treatment. </p> <p>This single‐centre study recruited participants who met the international diagnostic criteria for Marfan syndrome (<a href="./references#CD011103-bbs2-0007" title="BeightonP , dePaepeA , DanksD , FinidoriG , Gedde‐DahlT , GoodmanR , et al. International nosology of heritable disorders of connective tissue, Berlin, 1986. American Journal of Medical Genetics1988;29:581‐94. ">Beighton 1988</a>) within one year of trial initiation. Participants less than 12 or more than 50 years old, or receiving ongoing treatment with propranolol were excluded. Other exclusion criteria included: aortic dissection, aortic regurgitation on auscultation, moderate or severe mitral regurgitation, previous cardiovascular surgery, dyspnea during moderate exercise, orthopnoea, peripheral oedema, left ventricular ejection fraction less than 50%, atrioventricular conduction delay of any degree, and disorders where propranolol was contraindicated. </p> <p>Of 117 people considered for the study, 93 were eligible and 70 provided informed consent. Participants were randomised after giving consent by assigning the next available number on a list derived from a table of random numbers. 38 participants with even numbers received no treatment (control group) and 32 participants with odd numbers received propranolol (treatment group). Participants who were eligible for the study but who chose not to participate did not differ appreciably in any of the characteristics from participants in the control and treatment groups combined. </p> <p>The two study groups were matched for sex (male:female, control 19:18, treatment 20:12), mean age (control vs treatment; 14.5 years vs 15.4 years), and proportion of participants less than 18 years old. Baseline cardiovascular characteristics including aortic root diameter, presence of mitral‐valve prolapse or regurgitation, blood pressure, heart rate and systolic time interval were recorded. In the treatment group, male participants had a significantly lower resting heart rate compared to the female participants. Additionally, the treatment group had a significantly greater aortic diameter at baseline compared to the control group, but did not differ significantly in aortic ratio. </p> <p>Neither participant nor investigator was blinded to the study. The initial dose of propranolol was 10 mg four times daily in the treatment group. This was adjusted according to individual response of heart rate to exercise and systolic interval, assessed after two to four weeks of initiation. Optimal dose was reached when the heart rate remained below 100 beats per minute during exercise or the systolic time interval increased by 30%. The mean (± standard error (SE)) dose of propranolol was 212 ± 68 mg given in four divided doses daily. The time‐point at which this optimal dose was achieved is not provided. </p> <p>Participants were reviewed every 6 to 12 months with history and physical examination, electrocardiography and echocardiography. Serum drug concentration and phonocardiography to measure the left ventricular systolic time interval were also evaluated in the treatment group to assess for optimal dosing. </p> <p>Participants remained in the study until one of the following endpoints was reached: voluntary withdrawal, death, aortic dissection, aortic regurgitation detected by auscultation, cardiovascular surgery, congestive heart failure or an intractable adverse reaction to propranolol. The published study states that all comparisons of the two study groups included all participants, according to the intention‐to‐treat (ITT) principle. However, the study authors, through personal communication, confirmed that no clinically relevant endpoints were collected during the follow‐up period of 9.3 years in the control group and 10.7 years in the treatment group, therefore they did not perform an ITT analysis at the end of follow‐up. </p> <p>Further details of the included study are presented in <a href="./references#CD011103-sec-0098" title="">Characteristics of included studies</a>. </p> </section> <section id="CD011103-sec-0056"> <h4 class="title">Excluded studies</h4> <p>We obtained the full‐text versions for fifteen studies in total. Reasons for exclusion of five studies are presented in <a href="./references#CD011103-sec-0099" title="">Characteristics of excluded studies</a>. The other nine studies were not RCTs and did not meet the inclusion criteria. </p> </section> </section> <section id="CD011103-sec-0057"> <h3 class="title">Risk of bias in included studies</h3> <p>We have summarised the risk of bias of the included study (<a href="./references#CD011103-bbs2-0001" title="ShoresJ , BergerKR , MurphyEA , PyeritzRE . Progression of aortic dilatation and the benefit of long term beta‐adrenergic blockade in Marfan's syndrome. New England Journal of Medicine1994;330(9):1335‐41. ">Shores 1994</a>) in <a href="#CD011103-fig-0002">Figure 2</a> and also provided a detailed explanation in the 'Risk of bias' table. Based on the information available in the published study and through personal communication with the study authors, we considered the trial to have a low risk of random sequence generation (selection) bias and a high risk of allocation concealment (selection) bias. There was high risk of performance bias, detection bias, attrition bias and reporting bias, and an unclear risk of other bias. </p> <div class="figure" id="CD011103-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD011103-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_n/nCD011103-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD011103-sec-0058"> <h4 class="title">Allocation</h4> <p>After obtaining consent, participants were randomised by assigning the next available number from a list derived from a table of random numbers at the beginning of the study. Participants with an even number received no treatment (control group), and participants with an odd number received propranolol (treatment group). We therefore judged the study at low risk of bias for random sequence generation, however, the study author, through personal communication, stated that investigators were aware of treatment allocation and therefore we judged the study at high risk of bias for allocation concealment. </p> </section> <section id="CD011103-sec-0059"> <h4 class="title">Blinding</h4> <p>This was an open‐label study with both participants and investigators aware of treatment allocation and therefore at high risk of performance bias. Echocardiographic data were interpreted throughout the study by the same investigator who was unaware of the participant's identity, age, study group, or the sequence of multiple tracings, and therefore considered low risk of bias. However, for all other outcomes, we judged a high risk of detection bias as outcome assessors were not blinded. </p> </section> <section id="CD011103-sec-0060"> <h4 class="title">Incomplete outcome data</h4> <p>Withdrawal due to clinical end‐points was described, but the total withdrawals from the study was not. Furthermore, once participants reached a clinical end‐point, they were withdrawn and further follow‐up was not documented (confirmed by the study author). The published study states that all comparisons included all participants according to the ITT principle. However, the study author, through personal communication, confirmed that no clinically relevant endpoints were collected during the follow‐up period of 9.3 years in the control group and 10.7 years in the treatment group, therefore they did not perform an ITT analysis at the end of follow‐up. We therefore judged the study at high risk of attrition bias. The study author stated that there were no missing data and the last observation was carried forward. </p> </section> <section id="CD011103-sec-0061"> <h4 class="title">Selective reporting</h4> <p>We judged the study at high risk of reporting bias. The study protocol was not available and this was confirmed by the author through personal communication. Not all endpoints described in the methods are reported in the published study including: voluntary withdrawal, cardiovascular surgery, congestive heart failure indicated by new‐onset dyspnoea, orthopnoea, peripheral oedema, or fatigability associated with a left ventricular ejection fraction of less than 40%, and intractable adverse reaction to propranolol. Data regarding two of these outcomes: cardiovascular surgery and congestive heart failure, were provided by the study author through personal communication. Additionally, in the published study, it appears that "aortic root &gt; 6 cm" was added as a clinical end‐point in addition to those stated in the methods section, however the study author states that this was a pre‐determined clinical end‐point. Furthermore, adverse effects data were not collected systematically between groups as the study was not blinded or placebo‐controlled. The study stated that a propranolol dose reduction from 80 mg to 40 mg was required for one participant who developed third‐degree atrioventricular block. Personal communication with the study author reports that no adverse events occurred in the control group. </p> </section> <section id="CD011103-sec-0062"> <h4 class="title">Other potential sources of bias</h4> <p>This study was supported by grants from the National Institute of Health, the Food and Drug Administration and the National Marfan Foundation. However other bias is unclear as findings from this study have not been replicated as only a single study met the inclusion criteria. The study author, through personal communication, confirmed that no power calculation was performed to determine the sample size. </p> </section> </section> <section id="CD011103-sec-0063"> <h3 class="title" id="CD011103-sec-0063">Effects of interventions</h3> <p>See: <a href="./full#CD011103-tbl-0001"><b>Summary of findings for the main comparison</b> Beta‐blockers compared with placebo, no treatment or surveillance only for preventing aortic dissection in Marfan's syndrome</a> </p> <section id="CD011103-sec-0064"> <h4 class="title">Primary outcomes</h4> <section id="CD011103-sec-0065"> <h5 class="title">1. All‐cause mortality (including mortality attributed to Marfan syndrome)</h5> <p>Two deaths (2.8%) were observed in the study, both in the control group. The two participants, a 14 year‐old boy and an 18 year‐old woman, had mitral‐valve prolapse and a history of paroxysmal tachyarrhythmia (one of whom had Wolff‐Parkinson‐White syndrome). No aortic dissection or obvious cause of death was identified in postmortem examinations for either participant. The time points at which these participants died were not provided. No mortality attributed to Marfan syndrome was reported. There was no difference between the two study groups in all‐cause mortality (RR 0.24, 95% CI 0.01 to 4.75; participants = 70; studies = 1; low‐quality evidence). See <a href="./references#CD011103-fig-0003" title="">Analysis 1.1</a>. </p> </section> <section id="CD011103-sec-0066"> <h5 class="title">2. All non‐fatal serious adverse events (including all‐cause hospitalisations, cardiovascular events such as aortic dissection or rupture, and cardiovascular surgery) </h5> <p>All non‐fatal serious adverse events as defined above were not reported in the included study. </p> <p><b>Important non‐fatal clinical end points</b> </p> <p>Other morbidity outcomes as defined and reported by the <a href="./references#CD011103-bbs2-0001" title="ShoresJ , BergerKR , MurphyEA , PyeritzRE . Progression of aortic dilatation and the benefit of long term beta‐adrenergic blockade in Marfan's syndrome. New England Journal of Medicine1994;330(9):1335‐41. ">Shores 1994</a> study included aortic dissection, aortic regurgitation, congestive heart failure and cardiovascular surgery. </p> <p>Information regarding congestive heart failure and cardiovascular surgery were provided by the study author through personal communication. Cardiovascular surgery was indicated in participants when aortic root diameter reached 6 cm. </p> <p>Twelve participants in the control group and eight participants in the treatment group reached these non‐fatal clinical endpoints. However, two participants in the treatment group had never taken their propranolol. Analysis showed no difference between the two study groups (RR 0.79, 95% CI 0.37 to 1.69; participants = 70; studies = 1; low‐quality evidence). See <a href="./references#CD011103-fig-0004" title="">Analysis 1.2</a>. </p> <p>Acute aortic dissection was reported in four participants in the control group and two participants in the treatment group. Analysis showed no difference between the two study groups (RR 0.59, 95% CI 0.12 to 3.03; participants = 70; studies = 1; low‐quality evidence). See <a href="./references#CD011103-fig-0005" title="">Analysis 1.3</a>. </p> <p>Aortic regurgitation was reported in two participants in the control group and two participants in the treatment group. Analysis showed no difference between the two study groups (RR 1.19, 95% CI 0.18 to 7.96; participants = 70; studies = 1; low‐quality evidence) See <a href="./references#CD011103-fig-0006" title="">Analysis 1.4</a>. </p> <p>Congestive heart failure was reported in two participants in the control group and two participants in the treatment group. Analysis showed no difference between the two study groups (RR 1.19, 95% CI 0.18 to 7.96; participants = 70; studies = 1; low‐quality evidence) See <a href="./references#CD011103-fig-0007" title="">Analysis 1.5</a>. </p> <p>Cardiovascular surgery was reported in four participants in the control group and two participants in the treatment group. Analysis showed no difference between the two study groups (RR 0.59, 95% CI 0.12 to 3.03; participants = 70; studies = 1; low‐quality evidence) See <a href="./references#CD011103-fig-0008" title="">Analysis 1.6</a>. </p> </section> </section> <section id="CD011103-sec-0067"> <h4 class="title">Secondary outcomes</h4> <p><b>1. Measurements of the aortic root diameter taken by echocardiogram or other imaging modalities</b> </p> <p>Echocardiography was used to measure aortic diameter. M‐mode echocardiography was utilised until 1982 when cross‐sectional examinations were performed. The study states that for conformity, only M‐mode tracings by the leading‐edge method were analysed to determine aortic diameter. Maximal diameter, usually at the level of the sinuses, but occasionally at the sino‐tubular junction was measured in five consecutive cycles and averaged. We note that there is discrepancy between the manuscript text where it states that mean values were presented with standard errors, and the table of patient characteristics, where the values are stated as means with standard deviations. </p> <p>The two study groups differed significantly in their initial aortic diameter (control vs treatment: 30.2 mm vs 34.6 mm). Initial mean aortic ratio did not differ significantly (1.3 vs 1.4) and therefore we treated it as a co‐variable in the analysis. The aortic ratio was calculated by dividing the measured aortic diameter by the diameter predicted from the participant's height, weight and age. Of the two participants reaching the clinical endpoint of aortic root greater than 6 cm, the initial aortic ratio of one participant in the control group was 1.4 vs 2.1 in the other participant in the treatment group. <a href="#CD011103-tbl-0002">Table 1</a> provides information on the initial aortic diameter and ratio reported at baseline. </p> <div class="table" id="CD011103-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Initial aortic diameter and ratio reported at baseline</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Initial aortic diameter</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Control male (N = 19)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Control female (N = 19)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Treatment male (N = 20)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Treatment female (N = 12)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measured (mm) ± SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.1 ± 6.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.4 ± 6.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.7 ± 9.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.2 ± 5.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Expected (mm) ± SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.6 ± 3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.3 ± 3.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.5 ± 4.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.3 ± 4.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ratio</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 ± 0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 ± 0.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.43 ±0.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.37 ± 0.2</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>SD: standard deviation</p> </div> </div> <p>The study reports that the rate of aortic ratio increase was significantly lower in the treatment group compared to the control group (mean slope of the aortic ratio plotted against time for treatment vs control: 0.023 vs 0.083 per year), (t = 6.73, P &lt; 0.001; z = 6.64 by Mann Whitney nonparametric rank‐sum test, P &lt; 0.001). The study authors also report little, if any relation between the rate of change in aortic ratio and the initial aortic diameter. Additionally, analysis of covariance showed that adjustment for the initial aortic diameter had a negligible effect on the significance of the difference in the rates of enlargement. We were unable to measure the treatment effect on aortic ratio as these data were unavailable. </p> <p>The study states that participants from both study groups who reached an endpoint had higher average initial aortic ratios than the total study population. Again, data were unavailable to perform statistical analysis. </p> <p>The study does report on participants with aortic root diameter greater than 6 cm. One participant in the control group and one participant in the treatment group reached this end point. Although not stated in the published study, the study author, through personal communication, confirmed that this was a pre‐determined clinical end point. Analysis showed no difference between the two study groups (RR 1.19, 95% CI 0.08 to 18.24; participants = 70; studies = 1; low‐quality evidence) See <a href="./references#CD011103-fig-0009" title="">Analysis 1.7</a>. </p> <p><b>2. Systolic and diastolic blood pressure</b> </p> <p><a href="#CD011103-tbl-0003">Table 2</a> provides information on the blood pressure measured at baseline and during optimal dose. </p> <div class="table" id="CD011103-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Blood pressure measured at baseline and during optimal dose</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> BP measured as mmHg ±SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Control male (N = 19)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Control female (N = 19)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Treatment male (N = 20)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Treatment female (N = 12)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SBP at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>118 ± 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110 ± 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115 ± 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115 ± 14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DBP at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72 ± 11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 ± 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73 ± 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69 ± 13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SBP during optimal dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108 ± 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108 ± 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DBP during optimal dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66 ± 11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63 ± 7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BP: blood pressure; DBP: diastolic blood pressure; SBP: systolic blood pressure</p> </div> </div> <p>Systolic and diastolic blood pressure values were reported at baseline but not at study endpoint therefore we could not perform analysis of magnitude of blood pressure reduction between beta‐blocker and no‐treatment groups. </p> <p>Blood pressure data in the treatment group were reported when the optimal doses of propranolol were achieved. </p> <p> <ol id="CD011103-list-0008"> <li> <p>In the male treatment group, the study reported a significant decrease in blood pressure values during optimal treatment dose as compared to baseline (systolic: P = 0.006, diastolic: P = 0.045). </p> </li> <li> <p>In the female treatment group, the study reported a decrease in blood pressure values during optimal treatment dose as compared to baseline (systolic: P = 0.06, diastolic: P = 0.051) however, the P values were not significant. </p> </li> </ol> </p> <p><b>3. Total adverse events</b> </p> <p>As the study was not blinded or placebo‐controlled, the control group was not queried systematically about adverse symptoms. The investigators reported that there was no atrioventricular conduction delay in the control group. The study author, through personal email communication, provided additional information regarding adverse events in the control group (see <a href="#CD011103-tbl-0004">Table 3</a>, which provides information on adverse effects of long‐term treatment for 30 participants complying with beta‐blocker therapy). </p> <div class="table" id="CD011103-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse effects of long‐term treatment for 30 participants complying with beta‐blocker therapy</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Adverse effect</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Beta‐blocker group (N = 30)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Third‐degree heart block</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p>Not reported in <a href="./references#CD011103-bbs2-0001" title="ShoresJ , BergerKR , MurphyEA , PyeritzRE . Progression of aortic dilatation and the benefit of long term beta‐adrenergic blockade in Marfan's syndrome. New England Journal of Medicine1994;330(9):1335‐41. ">Shores 1994</a>, however, the study author reported that no adverse events </p> <p>occurred in the control group (personal communication)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐degree heart block</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lethargy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomina</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dream disturbance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild bronchospasm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Accentuated effects of alcohol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total with one or more effects</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>10</b> </p> </td> </tr> </tbody> </table> </div> <p><b>4. Withdrawals due to adverse events</b> </p> <p><a href="./references#CD011103-bbs2-0001" title="ShoresJ , BergerKR , MurphyEA , PyeritzRE . Progression of aortic dilatation and the benefit of long term beta‐adrenergic blockade in Marfan's syndrome. New England Journal of Medicine1994;330(9):1335‐41. ">Shores 1994</a> does not discuss any loss to follow‐up or withdrawals due to adverse events. The study author, through personal communication, confirmed that information on adverse events after participants withdrew from the study was not collected or documented. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011103-sec-0068" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011103-sec-0068"></div> <section id="CD011103-sec-0069"> <h3 class="title" id="CD011103-sec-0069">Summary of main results</h3> <p>The single study included in this review (<a href="./references#CD011103-bbs2-0001" title="ShoresJ , BergerKR , MurphyEA , PyeritzRE . Progression of aortic dilatation and the benefit of long term beta‐adrenergic blockade in Marfan's syndrome. New England Journal of Medicine1994;330(9):1335‐41. ">Shores 1994</a>) is an open‐label, randomised, single‐centre trial comparing beta‐blocker monotherapy with no treatment in 70 participants aged 12 to 50 years old with Marfan syndrome. Participants were randomly assigned to propranolol (N = 32) or control (N = 38) for an average duration of 9.3 years in the control group and 10.7 years in the treatment group. </p> <p>Propranolol was initiated at 10 mg four times daily, then individually up‐titrated to an optimal dose when the heart rate remained below 100 beats per minute during exercise or the systolic time interval increased by 30%. The mean (± SE) optimal dose of propranolol was 212 ± 68 mg given in four divided doses daily. </p> <p>There was no significant difference between the two study groups in all‐cause mortality. No mortality attributed to Marfan syndrome was reported. All non‐fatal serious adverse events were not reported. However, the study authors reported pre‐defined non‐fatal clinical endpoints that included aortic dissection, aortic regurgitation, congestive heart failure, and cardiovascular surgery. Their analysis showed no difference between the treatment and control groups in these outcomes. Additionally, beta‐blocker therapy did not reduce the incidence of acute aortic dissection, aortic regurgitation, congestive heart failure or cardiovascular surgery. </p> <p>The trial authors reported a significantly reduced rate of aortic dilatation measured by M‐mode echocardiography in the treatment group (aortic ratio mean slope: 0.084 (control) vs 0.023 (treatment), P &lt; 0.001). All other secondary outcomes (systolic and diastolic blood pressure, total adverse events and withdrawal due to adverse events) were not adequately reported in the treatment or control group at the study end‐point and therefore could not be analysed. </p> <p>We judged this trial to be at low risk of random sequence generation but high risk of selection (allocation concealment) bias, performance bias, detection bias, attrition bias and selective reporting bias. </p> </section> <section id="CD011103-sec-0070"> <h3 class="title" id="CD011103-sec-0070">Overall completeness and applicability of evidence</h3> <section id="CD011103-sec-0071"> <h4 class="title">Overall completeness</h4> <p>Only one RCT satisfied the inclusion criteria for this review. The sample size calculation was not reported. The power of the study to detect a difference in the aortic root dimensions (the primary outcome measure) was not reported. </p> <section id="CD011103-sec-0072"> <h5 class="title">Primary outcomes</h5> <p>Although all‐cause mortality from both study groups was reported, it was not the trial's primary outcome and considered as one of numerous clinical end‐points. It is therefore difficult to interpret all‐cause mortality, as participants withdrawn for other reasons were not followed up to the study's completion. We commend the average study duration (9.3 and 10.7 years in the control and treatment groups respectively), however, the rationale for this length is unclear as no protocol was available. Each participant differed in the length of follow‐up according to whether pre‐defined end‐points were reached, but individual participant data for this were not provided. The study authors report on the clinical end‐points reached, however no data were presented on other reasons for withdrawal. </p> <p>Other primary outcomes pre‐defined by the review were not fully reported in the published article as previously described. Personal communication with the study authors by email resulted in obtaining important information regarding other non‐fatal clinical outcomes such as congestive heart failure and participants undergoing cardiovascular surgery. </p> </section> <section id="CD011103-sec-0073"> <h5 class="title">Secondary outcomes</h5> <p>Aortic root dimensions, considered the primary outcome by <a href="./references#CD011103-bbs2-0001" title="ShoresJ , BergerKR , MurphyEA , PyeritzRE . Progression of aortic dilatation and the benefit of long term beta‐adrenergic blockade in Marfan's syndrome. New England Journal of Medicine1994;330(9):1335‐41. ">Shores 1994</a>, were measured by M‐mode echocardiography throughout the study duration to maintain conformity. This single modality is however a key limitation, as the current gold standards employ cardiovascular computed tomography (CT) or magnetic resonance imaging (MRI) to confirm the echocardiographic measurements of the aortic diameter (<a href="./references#CD011103-bbs2-0026" title="HiratzkaLF , BakrisGL , BeckmanJA , BersinRM , CarrVF , Casey JrDE , et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation2010;121:266‐369. ">Hiratzka 2010</a>, <a href="./references#CD011103-bbs2-0063" title="WrightJM , ConnollyHM . Management of Marfan syndrome and related disorders. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA (Accessed 9 April 2014). ">Wright 2012</a>). Although all echocardiographic data were interpreted by the same investigator, ruling out inter‐observer variability in the study, this measurement tool is still prone to intra‐observer variability and error. </p> <p>It is also important to note that the initial aortic diameter was significantly different between the study groups and the <a href="./references#CD011103-bbs2-0001" title="ShoresJ , BergerKR , MurphyEA , PyeritzRE . Progression of aortic dilatation and the benefit of long term beta‐adrenergic blockade in Marfan's syndrome. New England Journal of Medicine1994;330(9):1335‐41. ">Shores 1994</a> investigators accounted for this by measuring aortic ratio as a parameter and assessing the rate of change in aortic ratio as a function of the initial aortic diameter. However, they did not provide timelines for the two participants (one from each study group) who reached the clinical end‐point of aortic root greater than 6 cm despite the differing initial aortic ratios (1.4 in control, 2.1 in treatment). </p> <p>The rationale for the study was the effect of beta‐blockade on arterial haemodynamic function. Although the study provided blood pressure, heart rate and systolic time‐interval measurements at baseline for both study groups, these parameters were not provided for the study end‐point and only reported for the treatment group when optimal dose was achieved. Correlation with haemodynamic function with aortic root dimensions would have provided valuable information. </p> <p>Other limitations of the study are the open‐label design and lack of placebo in the control group. The adverse effects of long‐term beta‐blocker therapy were not reported in the published study for either group, however personal communication with the study authors confirmed that there were no adverse effects in the control group. The timeline to when the adverse effects reported for the treatment group have not been provided. Although the study states that serum propranolol levels were taken, these data were not available in the published manuscript. </p> </section> </section> <section id="CD011103-sec-0074"> <h4 class="title">Applicability of evidence</h4> <p>The authors of this review feel that the applicability of the evidence is limited and can be broadly summarised in two categories: </p> <section id="CD011103-sec-0075"> <h5 class="title">Intervention</h5> <p>Current guidelines recommend beta‐1 selective agents such as atenolol or metoprolol and it is therefore difficult to determine the appropriate dosing schedules for these drugs as this trial used propranolol. It is recommended that dosing is adjusted to maintain a heart rate after submaximal exercise to less than 100 beats per minute in adults and less than 110 beats per minute in children (<a href="./references#CD011103-bbs2-0063" title="WrightJM , ConnollyHM . Management of Marfan syndrome and related disorders. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA (Accessed 9 April 2014). ">Wright 2012</a>). </p> <p>When this study began, propranolol, a non‐selective beta‐adrenergic blocker was the only preparation available for clinical use. Propranolol was the only beta‐blocker studied as compared to control. We did not identify any RCTs comparing atenolol or metoprolol to control in people with Marfan syndrome. </p> </section> <section id="CD011103-sec-0076"> <h5 class="title">Population</h5> <p>This evidence cannot be applied to people with Marfan syndrome with aortic dissection, aortic regurgitation, moderate or severe mitral regurgitation, previous cardiovascular surgery, those with dyspnoea due to moderate exercise, orthopnoea or peripheral oedema, left ventricular ejection fraction of less than 50%, atrioventricular conduction delay of any degree, and those with disorders in which propranolol is contraindicated (diabetes mellitus or recurrent bronchospasm requiring medical treatment). </p> <p>Further, the current best recognised tool to diagnose Marfan syndrome is the Revised 2010 Ghent nosology criteria (<a href="./references#CD011103-bbs2-0034" title="LoeysBL , DietzHC , BravermanAC , CallewaertBL , DeBackerJ , DevereuxRB , et al. The revised Ghent nosology for the Marfan syndrome. Journal of Medical Genetics2010;47(7):476‐85. ">Loeys 2010</a>), first proposed in 1996 (<a href="./references#CD011103-bbs2-0015" title="DePaepeA , DevereuxRB , DietzHC , HennekamRC , PyeritzRE . Revised diagnostic criteria for the Marfan syndrome. American Journal of Medical Genetics1996;62(4):417. ">De Paepe 1996</a>) to overcome the tendency to over‐diagnose people with Marfan syndrome (<a href="./references#CD011103-bbs2-0064" title="WrightJM , ConnollyHM . Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders. In: UpToDate, Post TW (Ed), UpToDate, Waltham MA(Accessed June 2017). ">Wright 2016</a>). As participants in <a href="./references#CD011103-bbs2-0001" title="ShoresJ , BergerKR , MurphyEA , PyeritzRE . Progression of aortic dilatation and the benefit of long term beta‐adrenergic blockade in Marfan's syndrome. New England Journal of Medicine1994;330(9):1335‐41. ">Shores 1994</a> met the diagnostic criteria published by <a href="./references#CD011103-bbs2-0007" title="BeightonP , dePaepeA , DanksD , FinidoriG , Gedde‐DahlT , GoodmanR , et al. International nosology of heritable disorders of connective tissue, Berlin, 1986. American Journal of Medical Genetics1988;29:581‐94. ">Beighton 1988</a>, now largely considered a joint hypermobility score, it is possible that people without Marfan syndrome may have been included in the study. </p> <p>Male and female participants in both study groups had greater measured initial aortic diameter than expected values, therefore the results from the study cannot be applied to people without aortic dilatation at the initiation of beta‐blocker therapy. Furthermore, as children less than 12 years old were excluded, the outcomes can only be generalised to the adolescent and adult population although the study authors suggest earlier treatment provides greater benefit. </p> </section> </section> </section> <section id="CD011103-sec-0077"> <h3 class="title" id="CD011103-sec-0077">Quality of the evidence</h3> <p>Although the single included study is a RCT, which is considered the highest‐quality study design, we judged the evidence to be of low quality using the GRADE approach for all outcomes. The single included study was at high risk of selection (allocation concealment), performance, detection, attrition and selective reporting bias. Additionally, we further downgraded the evidence because we judged imprecision to be serious, due to very wide confidence intervals for all outcome measures. </p> <p>With the exception of mortality and aortic diameter, most other primary as well as secondary clinically relevant outcomes identified in this review were not adequately reported in the published manuscript. In this study when participants reached a pre‐defined end point, they were withdrawn from the trial and their follow‐up data were not reported. Adverse events data were poorly documented and therefore we could not evaluate the benefits versus harm of long‐term beta‐blocker therapy. </p> <p>Since we judged the single trial to be of low quality, our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. This study provides inadequate evidence to inform people with Marfan syndrome, and their families and care‐providers. </p> </section> <section id="CD011103-sec-0078"> <h3 class="title" id="CD011103-sec-0078">Potential biases in the review process</h3> <p>We performed a comprehensive literature search to identify all studies meeting the inclusion criteria from several databases. We did not limit our search to a particular language and we followed strictly the methodology described in the published protocol. </p> <p>Only one randomised trial met the inclusion criteria, therefore study findings have not been replicated. It was not possible to collect all relevant information for the pre‐defined outcomes outlined in this review as they were not reported in the published study. However, we successfully contacted the study authors and obtained additional information. </p> </section> <section id="CD011103-sec-0079"> <h3 class="title" id="CD011103-sec-0079">Agreements and disagreements with other studies or reviews</h3> <p>The present study is the only RCT that compares beta‐blocker therapy with no treatment in Marfan syndrome. Although RCTs are considered the highest level of evidence, we recognise that data are available from non‐randomised studies on beta‐blocker monotherapy in Marfan syndrome and provide valuable information. </p> <p>Several retrospective and prospective studies evaluating the efficacy of beta‐blocker therapy have demonstrated conflicting results and we have summarised these in Additional <a href="#CD011103-tbl-0005">Table 4</a>. </p> <div class="table" id="CD011103-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Additional retrospective and prospective studies evaluating beta‐blocker therapy versus no treatment</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study design</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Results</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Conclusions</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0030" title="LadouceurM , FermanianC , LupoglazoffJM , EdouardT , DulacY , AcarP , et al. Effect of beta blockade on ascending aortic dilatation in children with the Marfan syndrome. American Journal of Cardiology2007;99:406‐9. ">Ladouceur 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0009"> <li> <p>Retrospective, multicentre study evaluating the evolution of aortic diameter in children with Marfan syndrome, receiving beta‐blocker initiated before 12 years of age (N = 77) compared to no treatment (N = 78) </p> </li> <li> <p>Beta blockers: atenolol (70%), nadolol (17%) and propranolol (6%)</p> </li> <li> <p>Treatment was initiated according to physician's practice: at diagnosis or documentation of aortic root dilatation. </p> </li> <li> <p>Aortic diameters were measured annually by echocardiography</p> </li> <li> <p>Follow up: &lt; 5 years</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0010"> <li> <p>155 children (82 boys, 73 girls) from 3 outpatient clinics in France</p> </li> <li> <p>&lt; 12 years at diagnosis</p> </li> <li> <p>Mean age at diagnosis in years: 6.1 ± 3.2 (treatment), 7.4 ± 5.2 (no treatment)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0011"> <li> <p>2 study groups were similar in age, height, weight, BP and heart rate at the time of diagnosis </p> </li> <li> <p>Aortic root dilatation was more frequent in the treatment group.</p> </li> <li> <p>Beta‐blocker therapy was started at an average of 1.3 years after diagnosis in the treatment group (mean age 7.5 ± 3.2 years). </p> </li> <li> <p>4 participants died in total (3 sudden deaths, 1 respiratory distress): 3 were from the control group </p> </li> <li> <p>2 of 77 children taking beta‐blockers stopped treatment during the study</p> </li> <li> <p>Adverse effects were not reported</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0012"> <li> <p>Beta‐blockade significantly decreased the rate of aortic dilatation by a mean of 0.16 mm/year compared with untreated participants (P = 0.0383) </p> </li> <li> <p>Very few mortality and morbidity events prevent further interpretation regarding the potential for harm. </p> </li> <li> <p>The study authors recommend treatment as soon as the diagnosis is made</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0032" title="LeggetME , UngerTA , O'SullivanCK , ZwinkTR , BennettRL , ByersPH , et al. Aortic root complications in Marfan's syndrome: identification of a lower risk group. Heart1996;75:389‐95. ">Legget 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0013"> <li> <p>Purpose of this study was to examine clinical and echocardiographic predictors of outcome in Marfan syndrome (N = 83) </p> </li> <li> <p>Follow‐up: mean = 4 years, range = &lt; 1‐16 years</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0014"> <li> <p>36% participants received beta‐blocker treatment for &gt; 1 year, 64% never received or received for &lt; 1 year </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0015"> <li> <p>Aortic ratios and the change in ratio between initial and final echocardiograms did not differ between the beta‐blocker and no‐beta‐blocker groups </p> </li> <li> <p>58 participants on beta‐blocker treatment reached a clinical event (defined as death or surgery for ascending aortic dissection or aneurysm) while 37 did not. Those who reached an event were on beta‐blocker therapy for a mean of 40 months compared to 20 months in those who didn't have a clinical event. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0016"> <li> <p>Actuarial freedom from all events was no different in those receiving beta‐blockers compared with those not receiving beta‐blockers at 5 years </p> </li> <li> <p>The study authors state the limitations of their study make interpretation of the data pertaining to beta‐blocker treatment difficult. </p> </li> <li> <p>A low‐risk subgroup of people with Marfan syndrome can be identified as those with aortic ratio &lt; 1.3 and annual change in aortic ratio &lt; 5% </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0042" title="PhomakayV , HuettWG , GossettJM , TangX , BornemeierRA , CollinsRT . β‐Blockers and angiotensin converting enzyme inhibitors: comparison of effects on aortic growth in pediatric patients with Marfan syndrome. Journal of Pediatrics2014;165:951‐5. ">Phomakay 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0017"> <li> <p>Retrospective, single‐centre study comparing the effect of beta‐blockers vs ACE‐inhibitors vs no treatment on aortic root growth rate in people with Marfan syndrome. A normal control group was also included. </p> </li> <li> <p>Pharmacological choice was provider‐dependent and initiated based on aortic measurements or accelerated dilatation. </p> </li> <li> <p>Beta blockers: atenolol (45.9%), metoprolol (48.5%), propranolol (5.6%)</p> </li> <li> <p>ACEI: daily lisinopril (12.9%), enalapril (85.5%), captopril (1.6%)</p> </li> <li> <p>Aortic measurements performed by echocardiography</p> </li> <li> <p>Mean follow‐up: 7.6 ± 5.8 years</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0018"> <li> <p>67 participants with confirmed Marfan syndrome (34 female, 33 male)</p> </li> <li> <p>Mean age at first encounter: 13 ± 10 years</p> </li> <li> <p>Mean age for untreated group: 9.8 years, beta‐blocker therapy: 16.9 years, ACEI: 16.8 years </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0019"> <li> <p>Beta‐blocker group had significantly lower heart rate but no difference in BP compared to untreated group. </p> </li> <li> <p>ACE inhibitor group had significantly higher BP compared to beta‐blocker and untreated group. The heart rate was lower compared to the untreated group, but no difference compared to the beta‐blocker group. </p> </li> <li> <p>AGV was significantly attenuated in the beta‐blocker group.</p> </li> <li> <p>Total of 1 participant died; study group not specified</p> </li> <li> <p>Total of 14 participants underwent surgeries (aortic root replacement in 11/14; median age 17 years). </p> </li> <li> <p>2 participants experienced aortic dissections: 1 from the beta‐blocker group, 1 from ACEI group </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0020"> <li> <p>Beta‐blocker therapy resulted in near normalisation of AGV</p> </li> <li> <p>ACEI did not significantly decrease AGV</p> </li> <li> <p>The study authors suggest early introduction of beta‐blocker therapy should be considered even prior to the demonstration of aortic dilatation. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0051" title="Rossi‐FoulkesR , RomanMJ , RosenSE , Kramer‐FoxR , EhlersKH , O'LoughlinJE , et al. Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome. American Journal of Cardiology1999;83:1364‐68. ">Rossi‐Foulkes 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0021"> <li> <p>Prospective, non‐randomised, non‐blinded study.</p> </li> <li> <p>Treatment (N = 27): beta‐blockers in most participants, verapamil in 1 Verapamil with asthma </p> </li> <li> <p>No treatment (N = 15)</p> </li> <li> <p>Dosage was adjusted to achieve maximally tolerated decrease in heart rate and BP</p> </li> <li> <p>Aortic measurements by echocardiography</p> </li> <li> <p>Follow‐up: 44 ± 24 months</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0022"> <li> <p>43 children (28 boys, 25 girls) with Marfan syndrome</p> </li> <li> <p>11 participants from non‐treatment group crossed over to the treatment group</p> </li> <li> <p>Average age at initial evaluation: 9.4 ± 5.3 years). Range 0.5‐17.8 years</p> </li> <li> <p>No treatment group: either none was recommended, or parental/participant refusal</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0023"> <li> <p>No significant difference in age, body size, BP, ocular, skeletal, cardiovascular abnormalities between male and female participants at baseline </p> </li> <li> <p>Aortic root dilatation was present in 79% of participants at initial evaluation</p> </li> <li> <p>Treated (beta‐blocker and calcium channel blocker) participants had slower aortic growth than untreated participants </p> </li> <li> <p>Major cardiovascular complications developed in 5 participants despite long‐term pharmacologic therapy: mitral regurgitation and aortic regurgitation, distal aortic dissection, and cardiovascular surgery </p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0024"> <li> <p>The study reports a beneficial impact of drug therapy on the absolute and relative rates of aortic root growth in children with Marfan syndrome </p> </li> <li> <p>The study authors report however, all aortic complications occurred in participants on long‐term therapy and therefore improved survival may be more fundamentally related to improved detection and appropriately timed surgical intervention. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0053" title="SalimMA , AlpertBS , WardJC , PyeritzRE . Effect of beta‐adrenergic blockade on aortic root rate of dilation in the Marfan syndrome. American Journal of Cardiology1994;74:629‐33. ">Salim 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0025"> <li> <p>Retrospective, non‐randomised study comparing beta‐blocker (N = 100) vs no treatment (N = 13) </p> </li> <li> <p>Beta‐blocker dose was achieved on basis of exercise challenge</p> </li> <li> <p>Beta blockers: propranolol and atenolol</p> </li> <li> <p>Aortic root diameter measured by Echocardiogram, CT or MRI</p> </li> <li> <p>Follow‐up: approximate range: 2‐8 years</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0026"> <li> <p>113 participants at 2 centres</p> </li> <li> <p>Control group: those who couldn't or wouldn't take beta‐blocker therapy</p> </li> <li> <p>Age &lt; 21 years at initial visit</p> </li> <li> <p>Mean age (years): control 10.2 ± 4.6, treatment: 14.1 ± 3.4 in 1 centre, 10.4 ± 3.4 in the other centre </p> </li> <li> <p>Heart rate and BP were used as measures of dosing and treatment efficacy</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0027"> <li> <p>Mean aortic root diameter ≥ 95th percentile for the normal population</p> </li> <li> <p>Mean aortic root diameter was similar among groups at baseline</p> </li> <li> <p>Mean aortic diameter was significantly larger in the control group</p> </li> <li> <p>5 participants from the treated group required aortic valve replacement.</p> </li> <li> <p>Initial and final aortic root diameters in the surgical‐treated group was significantly larger than in remaining participants in the treated group </p> </li> <li> <p>Rapid increase in aortic root diameter during prepubertal and early pubertal years with maximal rate of increase during years 6‐14 </p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0028"> <li> <p>Greatest rate of aortic root dilatation was observed in the group that didn't receive any therapy </p> </li> <li> <p>The study authors recommend that participants with Marfan syndrome should begin beta‐blocker at the earliest age possible with the dose titrated to the largest dose tolerated. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0054" title="Selamet TierneyES , FeingoldB , PrintzBF , ParkSC , GrahamD , KleinmanCS , et al. Beta‐blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome. Journal of Pediatrics2007;150:77‐82. ">Selamet Tierney 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0029"> <li> <p>Retrospective, multicentre study evaluating the rate of aortic dilatation in children with Marfan syndrome prescribed beta‐blockade therapy (N = 29) compared to no treatment (N = 34) </p> </li> <li> <p>Atenolol dose titrated to goal dose of 25 mg in children, 50 mg in adolescents</p> </li> <li> <p>Aortic diameters were measured by echocardiography at 18‐month to 3‐year intervals</p> </li> <li> <p>Follow‐up: 81 months in control group, 76 months in treated group</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0030"> <li> <p>63 participants with Marfan syndrome from 2 centres</p> </li> <li> <p>Age: ≤ 18 years</p> </li> <li> <p>Mean age: control v treatment: 9.2 v 8.8 years</p> </li> <li> <p>Baseline: both groups well matched for mean age, weight, height, body surface area, sex, heart rate and heart rate z‐score </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD011103-list-0031"> <li> <p>No significant difference in aortic root measurements at baseline or study end between the treatment and control groups. </p> </li> <li> <p>1 death in total from the control group: died peri‐operatively during aortic valve replacement </p> </li> <li> <p>3 participants in total underwent aortic root replacement: 1 participant in the treatment group had intervention after aortic dissection. 2 control participants underwent elective intervention) </p> </li> <li> <p>Side effects documented in 35% of the treatment group</p> </li> <li> <p>Similar symptoms reported in 21% of the untreated group</p> </li> <li> <p>Specific exercise testing to assess adequacy of beta‐blockade not routinely performed, but heart rate and heart rate z‐scores were lower in the treatment group. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0032"> <li> <p>Beta‐blocker therapy does not significantly alter the rate of aortic root dilatation in children with Marfan syndrome. </p> </li> <li> <p>Similar number of participants from both study groups reached clinical endpoints</p> </li> <li> <p>The authors recommend that life‐time beta‐blocker therapy during childhood be reconsidered given their study findings, the potential for side effects and the lack of favourable late outcome data. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0055" title="SilvermanDI , BurtonKJ , GrayJ , BosnerMS , KouchoukosNT , RomanMJ , et al. Life expectancy in the Marfan syndrome. American Journal of Cardiology1995;75(2):157‐60. ">Silverman 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0033"> <li> <p>Large retrospective study with primary goal to evaluate life‐expectancy in Marfan syndrome </p> </li> <li> <p>Beta‐blockers: propranolol, atenolol, metoprolol and nadolol</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0034"> <li> <p>419 participants with Marfan syndrome from 4 centres</p> </li> <li> <p>119 participants were on beta‐blocker therapy</p> </li> <li> <p>Mean age when beta‐blockade therapy was begun: 28 ± 14 years</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0035"> <li> <p>Mean age for living members of the treated group was 33 ± 14 years compared to 31 ± 17 years in those who had never received beta blockers (P = 0.29) </p> </li> <li> <p>Median cumulate probability in beta‐blocker group was 72 years, compared to 70 years with no treatment (P = 0.01) </p> </li> <li> <p>Of the 47 participants that died, 8 were taking beta‐blockers.</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0036"> <li> <p>Life expectancy for participants increased by &gt; 25%, due to an overall improved population life expectancy, benefits of cardiovascular surgery, and increased frequency of diagnosis. </p> </li> <li> <p>Study authors state that their study design doesn't permit direct assessment of beta‐blockade on survival, however, their data suggest that medical therapy with beta‐blocker confers benefit in survival. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0057" title="TaherniaAD . Cardiovascular anomalies in Marfan's syndrome: the role of echocardiography and b‐blockers. Southern Medical Journal1993;86:305‐10. ">Tahernia 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0037"> <li> <p>Prospective study assessing beta‐blocker therapy versus no treatment in 6 people with Marfan syndrome </p> </li> <li> <p>Aortic dimensions measured by echocardiography annually</p> </li> <li> <p>Propranolol 15 mg twice a day</p> </li> <li> <p>Follow‐up: 2‐5 years</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0038"> <li> <p>6 participants (3 on propranolol, 3 controls)</p> </li> <li> <p>Mean age at beginning of study: 10 years in the study group, 9 years in the control group </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0039"> <li> <p>Control group had mild‐moderate aortic dilatation, treatment group had moderate‐severe aortic dilatation </p> </li> <li> <p>3 participants on beta‐blocker: no further dilatation of the aortic annulus diameter and ascending aorta. No side effects were reported </p> </li> <li> <p>3 participants on no treatment: evidence of progressive dilatation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0040"> <li> <p>After 2‐5 years of follow‐up, no progressive aortic dilatation was seen in any of the participants receiving low‐dose beta‐blockers </p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ACEI: angiotensin‐converting enzyme inhibitor; AGV: aortic growth velocity; BP: blood pressure; CT: computerised tomography; MRI: magnetic resonance imaging </p> </div> </div> <section id="CD011103-sec-0080"> <h4 class="title">Beta‐blocker compared to no treatment</h4> <p>The non‐randomised, retrospective studies by <a href="./references#CD011103-bbs2-0030" title="LadouceurM , FermanianC , LupoglazoffJM , EdouardT , DulacY , AcarP , et al. Effect of beta blockade on ascending aortic dilatation in children with the Marfan syndrome. American Journal of Cardiology2007;99:406‐9. ">Ladouceur 2007</a> and <a href="./references#CD011103-bbs2-0053" title="SalimMA , AlpertBS , WardJC , PyeritzRE . Effect of beta‐adrenergic blockade on aortic root rate of dilation in the Marfan syndrome. American Journal of Cardiology1994;74:629‐33. ">Salim 1994</a> analysed the effect of beta‐blockade on aortic dilatation in participants with Marfan’s syndrome. Although Ladoceur and colleagues focused on a paediatric sub‐population (mean age at diagnosis: 6.7 years) and Salim and colleagues included an older, adolescent sub‐population less than 21 years of age, both studies reported that beta‐blocker therapy reduced the rate of aortic dilatation. We note that <a href="./references#CD011103-bbs2-0053" title="SalimMA , AlpertBS , WardJC , PyeritzRE . Effect of beta‐adrenergic blockade on aortic root rate of dilation in the Marfan syndrome. American Journal of Cardiology1994;74:629‐33. ">Salim 1994</a> had a small number of participants in the control group (N = 13), composed of patients who could not or would not take beta‐blockade therapy, compared to the beta‐blocker treatment group (N = 100). Beta‐blockers used in both studies were atenolol, nadolol and propranolol. In contrast, another retrospective study, <a href="./references#CD011103-bbs2-0058" title="TierneyESS , FeingoldB , PrintzBF , ParkSC , GrahamD , KleinmanCS , et al. Beta‐blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome. Journal of Pediatrics2007;150(1):77‐82. ">Tierney 2007</a>, demonstrated no significant difference between beta‐blocker therapy and no treatment over a six‐ to seven‐year follow‐up in a population less than 18 years old. Additionally there was no significant difference in clinical endpoints reached or adverse symptoms reported. Although specific exercise testing was not routinely used to assess optimal beta‐blockade dosing, the study authors report that the heart rate and heart rate z‐scores were significantly lower in the treatment group at the time of last follow‐up. </p> <p>We identified two prospective studies assessing beta‐blocker mono‐therapy compared to no treatment (<a href="./references#CD011103-bbs2-0051" title="Rossi‐FoulkesR , RomanMJ , RosenSE , Kramer‐FoxR , EhlersKH , O'LoughlinJE , et al. Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome. American Journal of Cardiology1999;83:1364‐68. ">Rossi‐Foulkes 1999</a>; <a href="./references#CD011103-bbs2-0057" title="TaherniaAD . Cardiovascular anomalies in Marfan's syndrome: the role of echocardiography and b‐blockers. Southern Medical Journal1993;86:305‐10. ">Tahernia 1993</a>). <a href="./references#CD011103-bbs2-0057" title="TaherniaAD . Cardiovascular anomalies in Marfan's syndrome: the role of echocardiography and b‐blockers. Southern Medical Journal1993;86:305‐10. ">Tahernia 1993</a> was a small study of six participants that reported that people with Marfan’s syndrome (N = 3) taking beta‐blockade therapy had no progression of aortic root dilatation. <a href="./references#CD011103-bbs2-0051" title="Rossi‐FoulkesR , RomanMJ , RosenSE , Kramer‐FoxR , EhlersKH , O'LoughlinJE , et al. Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome. American Journal of Cardiology1999;83:1364‐68. ">Rossi‐Foulkes 1999</a>, a non‐randomised, prospective study compared treatment with beta‐blocker or calcium channel blocker with no treatment in children with Marfan syndrome and reported a beneficial impact of drug therapy on the absolute and relative rates of aortic root growth. </p> <p><a href="./references#CD011103-bbs2-0032" title="LeggetME , UngerTA , O'SullivanCK , ZwinkTR , BennettRL , ByersPH , et al. Aortic root complications in Marfan's syndrome: identification of a lower risk group. Heart1996;75:389‐95. ">Legget 1996</a> and <a href="./references#CD011103-bbs2-0055" title="SilvermanDI , BurtonKJ , GrayJ , BosnerMS , KouchoukosNT , RomanMJ , et al. Life expectancy in the Marfan syndrome. American Journal of Cardiology1995;75(2):157‐60. ">Silverman 1995</a> were two retrospective studies. Although their primary endpoints did not include measuring the effects of beta‐blocker therapy in Marfan’s syndrome, they did include a subanalysis of the efficacy of beta‐blocker treatment in their published reports. <a href="./references#CD011103-bbs2-0055" title="SilvermanDI , BurtonKJ , GrayJ , BosnerMS , KouchoukosNT , RomanMJ , et al. Life expectancy in the Marfan syndrome. American Journal of Cardiology1995;75(2):157‐60. ">Silverman 1995</a>, a large retrospective, multi‐centre study of 417 participants with Marfan’s syndrome evaluating life‐expectancy in this population suggested that the 119 participants on a wide variety of types and dosages of beta‐blocker therapy conferred benefit for survival. The study did not report on aortic root changes. <a href="./references#CD011103-bbs2-0032" title="LeggetME , UngerTA , O'SullivanCK , ZwinkTR , BennettRL , ByersPH , et al. Aortic root complications in Marfan's syndrome: identification of a lower risk group. Heart1996;75:389‐95. ">Legget 1996</a> studied various clinical and echocardiographic predictors of outcome in Marfan’s syndrome and reported no change in aortic ratio between beta‐blocker therapy (N = 30) and no therapy (defined as never received or received for less than one year, N = 53), over a mean follow‐up of four years. </p> <p>Though the above studies suggest agreement with the included <a href="./references#CD011103-bbs2-0001" title="ShoresJ , BergerKR , MurphyEA , PyeritzRE . Progression of aortic dilatation and the benefit of long term beta‐adrenergic blockade in Marfan's syndrome. New England Journal of Medicine1994;330(9):1335‐41. ">Shores 1994</a> RCT in this review that beta‐blockers may decrease the rate of aortic dilatation, these studies must be interpreted with caution given their limitations, differences in study design and high risk of bias. </p> </section> <section id="CD011103-sec-0081"> <h4 class="title">Beta‐blocker compared to other anti‐hypertensives</h4> <p>The data comparing beta‐blocker therapy to other anti‐hypertensives are more robust. Although our review focus is beta‐blocker monotherapy, for the reasons outlined in the introduction, we provide a brief summary and outline of the literature below and in <a href="#CD011103-tbl-0006">Table 5</a>. We excluded the RCTs listed in this table from our review as they did not include a no‐treatment control group. </p> <div class="table" id="CD011103-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Additional retrospective and prospective studies evaluating beta‐blocker therapy versus other anti‐hypertensive treatment</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study design</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patient population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusions</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0002" title="BhattAB , BuckJS , ZuflachtJP , MilianJ , KadivarS , GuavreauK , et al. Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome. Vascular Medicine2015;20:317‐25. ">Bhatt 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0041"> <li> <p>Randomised, double‐blind, parallel trial of losartan vs atenolol comparing their effects on arterial stiffness and left ventricular function in adults with Marfan syndrome </p> </li> <li> <p>Losartan 100 mg 1/day</p> </li> <li> <p>Atenolol 50 mg 1/day</p> </li> <li> <p>Follow‐up: 6 months</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0042"> <li> <p>34 participants</p> </li> <li> <p>Age: &gt; 18 years</p> </li> <li> <p>Atenolol; N = 17</p> </li> <li> <p>Losartan; N = 17</p> </li> <li> <p>Mean age in losartan group: 36 years, atenolol group: 34 years</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0043"> <li> <p>2 study groups were similar in all pre‐treatment variables (age, gender, heart rate, BP, cardiac and aortic measurements) </p> </li> <li> <p>Atenolol decreased pulse wave velocity significantly compared to losartan. However, this improvement was attenuated when adjusted for change in heart rate. </p> </li> <li> <p>Losartan decreased central augmentation pressure significantly compared to atenolol</p> </li> <li> <p>No significant change in aortic root or ascending aortic diameter between the 2 study groups </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0044"> <li> <p>Both atenolol and losartan favourably affected aortic stiffness in adults with Marfan syndrome </p> </li> <li> <p>Different mechanisms on improving aortic functional properties are implicated</p> </li> <li> <p>Study authors suggest a role for both beta‐blockers and ARBs in the treatment of Marfan syndrome. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0003" title="FortezaA , EvangelistaA , SanchezV , Teixido‐TuraG , SanzP , GutierrezL , et al. Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial. European Heart Journal2016;37:978‐85. ">Forteza 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0045"> <li> <p>Phase IIIb, randomised, parallel, double‐blind study to determine the efficacy of losartan (N = 70) or atenolol (N = 70) in Marfan syndrome </p> </li> <li> <p>Follow‐up: 3 years</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0046"> <li> <p>140 participants from 2 clinical centres</p> </li> <li> <p>Mean age: range 5‐60 years</p> </li> <li> <p>Inclusion criteria: aortic root diameter &lt; 45 mm</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0047"> <li> <p>No serious drug‐related adverse effects observed</p> </li> <li> <p>Aortic root diameter increased significantly in both groups</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0048"> <li> <p>There was no significant difference in progression of aortic root and ascending aortic diameters between losartan and atenolol in participants with Marfan syndrome </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0004" title="LacroRV , DietzHC , SleeperLA , YetmanAT , BradleyTJ , ColanSD , et al. Atenolol versus losartan in children and young adults with Marfan's syndrome. New England Journal of Medicine2014;371:2061‐71. ">Lacro 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0049"> <li> <p>Randomised, multicentre trial comparing losartan (N = 305) with atenolol (N = 303) in children and young adults with Marfan syndrome </p> </li> <li> <p>Atenolol was increased on the basis of haemodynamic response to a maximum dose of 4 mg/kg daily </p> </li> <li> <p>Losartan was adjusted on the basis of body weight to a maximum dose of 1.4 mg/kg daily</p> </li> <li> <p>Aortic measurements performed by echocardiography every study visit, 6‐12 months apart</p> </li> <li> <p>Follow‐up: 3 years</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0050"> <li> <p>604 participants from 21 clinical centres</p> </li> <li> <p>Mean age: 11.5 in atenolol group, 11.0 in losartan. Range: 6 months‐25 years</p> </li> <li> <p>Aortic‐root z‐score was &gt; 3.0 in both groups</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0051"> <li> <p>Similar baseline clinical and echocardiographic characteristic between groups</p> </li> <li> <p>There was no significant difference in baseline‐adjusted rate of change in aortic‐root z‐score between the 2 study groups </p> </li> <li> <p>Small but significant difference in favour of atenolol in absolute diameter and z‐score for aortic annulus </p> </li> <li> <p>Both study groups indicated a decrease in the degree of aortic‐root dilatation relative to body‐surface area </p> </li> <li> <p>Younger age at baseline was associated with greater decrease in aortic‐root z‐score over time in both groups </p> </li> <li> <p>Diastolic BP was slightly lower in the atenolol group, but there were no differences in systolic or mean BPs </p> </li> <li> <p>Heart rate was significantly lower in the atenolol group</p> </li> <li> <p>There was no significant difference in 3 years in the rates of adverse clinical outcomes (aortic root surgery, aortic dissection, death) </p> </li> <li> <p>Rate of adverse events possibly higher in atenolol group, but no significant difference in serious adverse events </p> </li> <li> <p>No significant difference in withdrawal rate (11% per group) or median time to withdrawal.</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0052"> <li> <p>No significant difference in the rate of aortic root dilatation between the losartan and beta‐blocker therapy group among children and young adults with Marfan syndrome </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0005" title="SandorGGS , AlghamdiMH , RagginLA , PottsMT , WilliamsLD , PottsJE , et al. A randomized, double blind pilot study to assess the effects of losartan vs atenolol on the biophysical properties of the aorta in patients with Marfan and Loeys‐Dietz syndromes. International Journal of Cardiology2015;179:470‐5. ">Sandor 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0053"> <li> <p>Randomised, double‐blind. pilot study assessing the effects of losartan v atenolol on the biophysical properties of the aorta in Marfan and Loeys‐Dietz syndromes (LDS) </p> </li> <li> <p>Atenolol: 25 mg‐50 mg, losartan 25 mg daily</p> </li> <li> <p>Aortic dimensions measured by echocardiography prior to and after therapy</p> </li> <li> <p>Follow‐up: 12 months</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0054"> <li> <p>All 17 eligible participants were diagnosed with Marfan syndrome, 1 tested positive for both Marfan syndrome and LDS </p> </li> <li> <p>Atenolol group: 9 women</p> </li> <li> <p>Losartan group: 7 men, 1 woman</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0055"> <li> <p>Baseline height, weight, body surface area, body mass and BP were similar. There was a significant gender difference. </p> </li> <li> <p>No significant aortic root dilatations occurred during the trial.</p> </li> <li> <p>There was no significant difference for losartan to decrease pulse wave velocity and stiffness index </p> </li> <li> <p>There was no significant difference for atenolol to improve hydraulic power</p> </li> <li> <p>There was no decrease in contractility by atenolol</p> </li> <li> <p>Adverse effects were not reported</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0056"> <li> <p>Study authors cannot draw definite conclusions due to limitations of the study, but suggest atenolol and losartan have different mechanisms of action on vascular function </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0006" title="WilliamsA , KennyD , WilsonD , FagenelloG , NelsonM , DunstanF , et al. Effects of atenolol, perindopril and verapamil on haemodynamic and vascular function in Marfan syndrome ‐ a randomised, double‐blind, crossover trial. European Journal of Clinical Investigation2012;42(8):891‐99. ">Williams 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0057"> <li> <p>Randomised, double‐blind cross‐over trial assessing the effects of atenolol, perindopril and verapamil on haemodynamic and vascular function in Marfan syndrome </p> </li> <li> <p>Atenolol: 75 mg</p> </li> <li> <p>Perindopril 4 mg</p> </li> <li> <p>Verapamil 240 mg</p> </li> <li> <p>Echocardiographic measurements</p> </li> <li> <p>Follow‐up: 18 weeks</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0058"> <li> <p>18 participants from 2 tertiary congenital heart disease centres</p> </li> <li> <p>Mean age: 30.4 ± 11.7</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0059"> <li> <p>Aortic root dimensions &lt; 5 cm at study baseline</p> </li> <li> <p>All drug groups reduced central systolic BP and brachial pressure.</p> </li> <li> <p>Atenolol reduced heart rate and delayed aortic wave travel</p> </li> <li> <p>No‐drug group altered the pulse wave velocity</p> </li> <li> <p>No significant change in aortic root diameter between groups and between baseline and study endpoint </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0060"> <li> <p>All drug groups reduced peripheral and central systolic BP</p> </li> <li> <p>Study authors suggest beta‐blockers have a continuing role in the treatment of Marfan syndrome </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0065" title="YetmanAT , BornemeierRA , McCrindleBW . Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. American Journal of Cardiology2005;95:1125‐7. ">Yetman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0061"> <li> <p>Prospective, non‐randomised trial assessing the effects of enalapril vs beta‐blocker therapy in people with Marfan syndrome </p> </li> <li> <p>Beta‐blocker: propranolol or atenolol depending on participant weight. Dose titrated to maximum of 2 mg/kg daily for atenolol, 1 mg/kg twice daily for propranolol </p> </li> <li> <p>ACEI: enalapril. Titrated to maximum dose of 10 mg twice daily</p> </li> <li> <p>Doses adjusted according to adverse effects experienced by participant, not haemodynamic effects </p> </li> <li> <p>Bi‐annual echo‐cardiographic assessment</p> </li> <li> <p>Follow‐up: 3.0 ± 0.2 years</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0062"> <li> <p>57 participants: 32 enalapril, 24 atenolol, 2 propranolol</p> </li> <li> <p>Mean age at start of therapy (years): 12.8 ± 7.8</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0063"> <li> <p>Improved aortic distensibility and a reduced aortic stiffness index in participants receiving enalapril and subsequently associated with a slower rate of aortic growth </p> </li> <li> <p>6 participants from beta‐blocker group discontinued treatment due to adverse effects (depression, fatigue, short‐term memory loss), and subsequently enrolled to enalapril group </p> </li> <li> <p>1 death from beta‐blocker treatment group (documented ventricular tachyarrhythmia); no evidence of aortic dissection </p> </li> <li> <p>9 participants had aortic root replacement (2 from enalapril, 7 from the beta‐blocker group) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0064"> <li> <p>ACEI provide therapeutic benefit in adults with Marfan syndrome compared to beta‐blocker treatment </p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ACEI: ACEI: angiotensin‐converting enzyme inhibitor; ARB: angiotensin receptor blockers; BP: blood pressure </p> </div> </div> <p><a href="./references#CD011103-bbs2-0042" title="PhomakayV , HuettWG , GossettJM , TangX , BornemeierRA , CollinsRT . β‐Blockers and angiotensin converting enzyme inhibitors: comparison of effects on aortic growth in pediatric patients with Marfan syndrome. Journal of Pediatrics2014;165:951‐5. ">Phomakay 2014</a> was a retrospective study of 67 people, comparing the effects of beta‐blockers versus ACE inhibitors versus no treatment on aortic root growth rate in Marfan syndrome for an average of 7.6 years. A normal control group was also included. Beta‐blockers used were atenolol, metoprolol and propranolol, while the ACE inhibitors were lisinopril, enalapril and captopril. They reported that beta‐blocker therapy resulted in near normalisation of aortic growth velocity (AGV), while ACE inhibitors did not significantly attenuate AGV. Two participants experienced aortic dissections, one from the beta‐blocker group and the other from the ACE‐inhibitor group. In contrast, <a href="./references#CD011103-bbs2-0065" title="YetmanAT , BornemeierRA , McCrindleBW . Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. American Journal of Cardiology2005;95:1125‐7. ">Yetman 2005</a>, a prospective, non‐randomised trial assessing the effects of enalapril compared to beta‐blocker therapy in 57 participants over three years demonstrated that enalapril was superior to beta‐blocker in improving aortic distensibility and stiffness, with associated slower rate of aortic growth. Additionally, the study authors reported an increased number of adverse effects and participants undergoing aortic root replacement from the beta‐blocker group. One death occurred in the beta‐blocker group with documented ventricular tachyarrhythmia. </p> <p>Three small and relatively short RCTs (<a href="./references#CD011103-bbs2-0002" title="BhattAB , BuckJS , ZuflachtJP , MilianJ , KadivarS , GuavreauK , et al. Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome. Vascular Medicine2015;20:317‐25. ">Bhatt 2015</a>; <a href="./references#CD011103-bbs2-0005" title="SandorGGS , AlghamdiMH , RagginLA , PottsMT , WilliamsLD , PottsJE , et al. A randomized, double blind pilot study to assess the effects of losartan vs atenolol on the biophysical properties of the aorta in patients with Marfan and Loeys‐Dietz syndromes. International Journal of Cardiology2015;179:470‐5. ">Sandor 2015</a>; <a href="./references#CD011103-bbs2-0006" title="WilliamsA , KennyD , WilsonD , FagenelloG , NelsonM , DunstanF , et al. Effects of atenolol, perindopril and verapamil on haemodynamic and vascular function in Marfan syndrome ‐ a randomised, double‐blind, crossover trial. European Journal of Clinical Investigation2012;42(8):891‐99. ">Williams 2012</a>) evaluated the haemodynamic and biophysical aortic effects of pharmacological therapy in Marfan’s syndrome. <a href="./references#CD011103-bbs2-0006" title="WilliamsA , KennyD , WilsonD , FagenelloG , NelsonM , DunstanF , et al. Effects of atenolol, perindopril and verapamil on haemodynamic and vascular function in Marfan syndrome ‐ a randomised, double‐blind, crossover trial. European Journal of Clinical Investigation2012;42(8):891‐99. ">Williams 2012</a> assessed the efficacy of atenolol, perindopril and verapamil in 18 participants with a mean age of 30.4 years and reported that all drug groups reduced peripheral and central pressure. Atenolol further delayed aortic wave travel. No significant change in aortic diameter was observed over 18 weeks of follow‐up. <a href="./references#CD011103-bbs2-0002" title="BhattAB , BuckJS , ZuflachtJP , MilianJ , KadivarS , GuavreauK , et al. Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome. Vascular Medicine2015;20:317‐25. ">Bhatt 2015</a> and <a href="./references#CD011103-bbs2-0005" title="SandorGGS , AlghamdiMH , RagginLA , PottsMT , WilliamsLD , PottsJE , et al. A randomized, double blind pilot study to assess the effects of losartan vs atenolol on the biophysical properties of the aorta in patients with Marfan and Loeys‐Dietz syndromes. International Journal of Cardiology2015;179:470‐5. ">Sandor 2015</a> both compared the effects of losartan and atenolol and although they reported differing effects of atenolol on pulse wave velocity, concluded that atenolol and losartan had different mechanisms of action on aortic function, indicating a role for both in the treatment for Marfan’s syndrome. Neither study reported a significant change in aortic root dilatation for either treatment group over a study duration of 6 to 12 months. </p> <p>Two RCTs (<a href="./references#CD011103-bbs2-0003" title="FortezaA , EvangelistaA , SanchezV , Teixido‐TuraG , SanzP , GutierrezL , et al. Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial. European Heart Journal2016;37:978‐85. ">Forteza 2016</a>; <a href="./references#CD011103-bbs2-0004" title="LacroRV , DietzHC , SleeperLA , YetmanAT , BradleyTJ , ColanSD , et al. Atenolol versus losartan in children and young adults with Marfan's syndrome. New England Journal of Medicine2014;371:2061‐71. ">Lacro 2014</a>) have recently been published, comparing the effects of losartan and atenolol over a three‐year period. Neither had a no‐treatment control group. <a href="./references#CD011103-bbs2-0004" title="LacroRV , DietzHC , SleeperLA , YetmanAT , BradleyTJ , ColanSD , et al. Atenolol versus losartan in children and young adults with Marfan's syndrome. New England Journal of Medicine2014;371:2061‐71. ">Lacro 2014</a> recruited 604 participants distributed between 21 clinical centres and found no significant difference in the rate of aortic root dilatation between losartan and beta‐blocker treatment in children and young adults (age range: 6 to 25 years). They reported a possible higher rate of adverse events in participants treated with beta‐blockade, but there was no difference in adverse clinical outcomes between the two groups. Similarly, <a href="./references#CD011103-bbs2-0003" title="FortezaA , EvangelistaA , SanchezV , Teixido‐TuraG , SanzP , GutierrezL , et al. Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial. European Heart Journal2016;37:978‐85. ">Forteza 2016</a>, a randomised, parallel, double‐blind study reported no significant difference in the progression of aortic root and ascending aortic diameters between losartan and atenolol. Further, they demonstrated that aortic root diameter increased significantly in both groups. No serious adverse effects were observed in either treatment group. </p> </section> <section id="CD011103-sec-0082"> <h4 class="title">Comparison with other reviews</h4> <p>Two meta‐analyses have been conducted on the efficacy of beta‐blocker therapy versus no treatment in people with Marfan syndrome (<a href="./references#CD011103-bbs2-0019" title="GaoL , MaoQ , WenD , ZhangL , ZhouX , HuiR . The effect of beta‐blocker therapy on progressive aortic dilatation in children and adolescents with Marfan's syndrome: a meta‐analysis. Acta Paediatrica2011;100:101‐5. ">Gao 2011</a>; <a href="./references#CD011103-bbs2-0020" title="GersonyDR , McClaughlinMR , JinZ , GersonyWM . The effect of beta‐blocker therapy on clinical outcome in patients with Marfan's syndrome: a meta‐analysis. International Journal of Cardiology2007;114:303‐8. ">Gersony 2007</a>). </p> <p> <ol id="CD011103-list-0065"> <li> <p><a href="./references#CD011103-bbs2-0019" title="GaoL , MaoQ , WenD , ZhangL , ZhouX , HuiR . The effect of beta‐blocker therapy on progressive aortic dilatation in children and adolescents with Marfan's syndrome: a meta‐analysis. Acta Paediatrica2011;100:101‐5. ">Gao 2011</a> focused on a subpopulation of children and adolescents with Marfan syndrome and included five non‐randomised studies (<a href="./references#CD011103-bbs2-0030" title="LadouceurM , FermanianC , LupoglazoffJM , EdouardT , DulacY , AcarP , et al. Effect of beta blockade on ascending aortic dilatation in children with the Marfan syndrome. American Journal of Cardiology2007;99:406‐9. ">Ladouceur 2007</a>; <a href="./references#CD011103-bbs2-0051" title="Rossi‐FoulkesR , RomanMJ , RosenSE , Kramer‐FoxR , EhlersKH , O'LoughlinJE , et al. Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome. American Journal of Cardiology1999;83:1364‐68. ">Rossi‐Foulkes 1999</a>; <a href="./references#CD011103-bbs2-0053" title="SalimMA , AlpertBS , WardJC , PyeritzRE . Effect of beta‐adrenergic blockade on aortic root rate of dilation in the Marfan syndrome. American Journal of Cardiology1994;74:629‐33. ">Salim 1994</a>; <a href="./references#CD011103-bbs2-0057" title="TaherniaAD . Cardiovascular anomalies in Marfan's syndrome: the role of echocardiography and b‐blockers. Southern Medical Journal1993;86:305‐10. ">Tahernia 1993</a>; <a href="./references#CD011103-bbs2-0058" title="TierneyESS , FeingoldB , PrintzBF , ParkSC , GrahamD , KleinmanCS , et al. Beta‐blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome. Journal of Pediatrics2007;150(1):77‐82. ">Tierney 2007</a>) to assess the effectiveness of beta‐blocker therapy on aortic dilatation and clinical outcomes (death, cardiovascular surgery, aortic dissection or rupture). Out of a study population of 392 children and adolescents less than 18 years old, their meta‐analysis reported a significantly decreased rate of aortic dilatation with treatment (SMD ‐1.30, 95% CI ‐2.11 to ‐0.49, P = 0.002). There was no significant difference in clinically important endpoints (death, cardiovascular surgery, or aortic dissection or rupture). Beta‐blockers used were mainly atenolol or propranolol. The authors acknowledge an important limitation of their analysis in that the measured aortic change was not normalised to body size as these data were not reported in their selected studies. However, they recognise that adiposity is often reduced in their young study population and state that reporting on absolute diameter is appropriate. </p> </li> <li> <p>In contrast, <a href="./references#CD011103-bbs2-0020" title="GersonyDR , McClaughlinMR , JinZ , GersonyWM . The effect of beta‐blocker therapy on clinical outcome in patients with Marfan's syndrome: a meta‐analysis. International Journal of Cardiology2007;114:303‐8. ">Gersony 2007</a> report from their meta‐analysis that there is no evidence of clinical benefit from long‐term beta‐blockade in people with Marfan syndrome. Their analysis imposed no restriction on age and included six studies, one of which was the RCT included in this review (<a href="./references#CD011103-bbs2-0001" title="ShoresJ , BergerKR , MurphyEA , PyeritzRE . Progression of aortic dilatation and the benefit of long term beta‐adrenergic blockade in Marfan's syndrome. New England Journal of Medicine1994;330(9):1335‐41. ">Shores 1994</a>), two non‐randomised, prospective studies, and three studies that were not designed to observe the effect of beta‐blocker therapy. Clinical endpoints were defined as aortic dissection or rupture, cardiovascular surgery or death. Aortic root dimensions were not included in the analysis. Beta‐blockers included in the studies were mainly atenolol and propranolol, but one study (<a href="./references#CD011103-bbs2-0055" title="SilvermanDI , BurtonKJ , GrayJ , BosnerMS , KouchoukosNT , RomanMJ , et al. Life expectancy in the Marfan syndrome. American Journal of Cardiology1995;75(2):157‐60. ">Silverman 1995</a>) additionally included nadolol and metoprolol. Out of 433 participants in the treatment group and 369 participants in the untreated group, participants on beta‐blocker therapy were more likely to reach a clinical endpoint using a fixed‐effects model (odds ratio (OR) 1.50, 95% CI 1.05 to 2.16). However, when a random‐effects model was applied, no statistical significance was reached for treatment effect (OR 1.54, 95% CI 0.99 to 2.40). The authors acknowledge that the length of time on beta‐blocker treatment was not included in three selected studies and the presence or non‐presence of advanced aortic disease was not included in the analysis. </p> </li> </ol> </p> <p>These two meta‐analyses report contradicting conclusions on the efficacy of beta‐blocker therapy but they are both limited by the heterogeneous design of the included studies and the combination of randomised and non‐randomised data. <a href="./references#CD011103-bbs2-0019" title="GaoL , MaoQ , WenD , ZhangL , ZhouX , HuiR . The effect of beta‐blocker therapy on progressive aortic dilatation in children and adolescents with Marfan's syndrome: a meta‐analysis. Acta Paediatrica2011;100:101‐5. ">Gao 2011</a>'s conclusion that beta‐blocker therapy can significantly slow the progression of aortic dilatation is in keeping with our single included RCT. </p> <p>A recent review by <a href="./references#CD011103-bbs2-0056" title="SinghMN , LacroRV . Recent clinical drug trials evidence in Marfan syndrome and clinical implications. Canadian Journal of Cardiology2016;32:66‐77. ">Singh 2016</a> provides a comprehensive summary on recent clinical drug trials and clinical implications in Marfan syndrome. This publication presents data comparing the various groups of anti‐hypertensive medications that have been examined for their prophylactic effectiveness on aortic dilatation including beta‐blockers, ARBs with and without baseline beta‐blocker therapy, and ACE inhibitors. The report concludes that medical therapy in Marfan syndrome should be individualised according to patient tolerance and various risk factors including age and family history of aortic dissection. The authors of <a href="./references#CD011103-bbs2-0056" title="SinghMN , LacroRV . Recent clinical drug trials evidence in Marfan syndrome and clinical implications. Canadian Journal of Cardiology2016;32:66‐77. ">Singh 2016</a> recommend that those with aortic root dilatation should receive therapy with adequate doses of either a beta‐blocker or ARB, and if severe, a combination of these therapies should be considered. They state that the evidence for prophylactic medication in people without aortic dilatation is less clear. </p> <p>In summary, the above comparisons with other identified studies and reviews are suggestive that beta‐blocker therapy may decrease the rate of aortic root dilatation in Marfan syndrome. However, our review specifically sought to examine the effect of beta‐blockers in the prevention of aortic dissection, the significant contributor to morbidity and mortality in this disease, and this outcome along with additional clinical adverse events remain inadequately addressed. </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011103-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/urn:x-wiley:14651858:media:CD011103:CD011103-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_t/tCD011103-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD011103-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_n/nCD011103-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/full#CD011103-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_n/nCD011103-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011103-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/urn:x-wiley:14651858:media:CD011103:CD011103-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_t/tCD011103-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD011103-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_n/nCD011103-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/full#CD011103-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_n/nCD011103-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011103-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/urn:x-wiley:14651858:media:CD011103:CD011103-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_t/tCD011103-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta‐blocker versus no treatment, Outcome 1 All‐cause mortality." data-id="CD011103-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_n/nCD011103-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Beta‐blocker versus no treatment, Outcome 1 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/references#CD011103-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_n/nCD011103-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011103-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/urn:x-wiley:14651858:media:CD011103:CD011103-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_t/tCD011103-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta‐blocker versus no treatment, Outcome 2 Clinically important non‐fatal endpoints as defined by Shores 1994." data-id="CD011103-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_n/nCD011103-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Beta‐blocker versus no treatment, Outcome 2 Clinically important non‐fatal endpoints as defined by Shores 1994. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/references#CD011103-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_n/nCD011103-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011103-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/urn:x-wiley:14651858:media:CD011103:CD011103-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_t/tCD011103-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta‐blocker versus no treatment, Outcome 3 Acute aortic dissection." data-id="CD011103-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_n/nCD011103-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Beta‐blocker versus no treatment, Outcome 3 Acute aortic dissection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/references#CD011103-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_n/nCD011103-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011103-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/urn:x-wiley:14651858:media:CD011103:CD011103-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_t/tCD011103-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta‐blocker versus no treatment, Outcome 4 Aortic regurgitation." data-id="CD011103-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_n/nCD011103-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Beta‐blocker versus no treatment, Outcome 4 Aortic regurgitation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/references#CD011103-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_n/nCD011103-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011103-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/urn:x-wiley:14651858:media:CD011103:CD011103-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_t/tCD011103-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta‐blocker versus no treatment, Outcome 5 Congestive heart failure." data-id="CD011103-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_n/nCD011103-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Beta‐blocker versus no treatment, Outcome 5 Congestive heart failure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/references#CD011103-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_n/nCD011103-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011103-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/urn:x-wiley:14651858:media:CD011103:CD011103-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_t/tCD011103-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta‐blocker versus no treatment, Outcome 6 Cardiovascular surgery." data-id="CD011103-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_n/nCD011103-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Beta‐blocker versus no treatment, Outcome 6 Cardiovascular surgery.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/references#CD011103-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_n/nCD011103-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011103-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/urn:x-wiley:14651858:media:CD011103:CD011103-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_t/tCD011103-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta‐blocker versus no treatment, Outcome 7 Aortic root diameter &gt; 6 cm." data-id="CD011103-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_n/nCD011103-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Beta‐blocker versus no treatment, Outcome 7 Aortic root diameter &gt; 6 cm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/references#CD011103-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/media/CDSR/CD011103/image_n/nCD011103-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011103-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Beta‐blockers compared with placebo, no treatment or surveillance only for preventing aortic dissection in Marfan's syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Beta‐blockers compared with placebo, no treatment or surveillance only for preventing aortic dissection in Marfan syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: people with confirmed diagnosis of Marfan syndrome </p> <p><b>Settings</b>: outpatient </p> <p><b>Intervention</b>: beta‐blockers </p> <p><b>Comparison</b>: placebo or no treatment or surveillance only </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> <p><b>Follow‐up: mean 9.3 years in control group and 10.7 years in treatment group</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b> Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Risk with placebo, no treatment or surveillance only</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Risk with beta blockers</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> </p> <p>(1 to 250)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.24</b> </p> <p>(0.01 to 4.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> L<b>ow<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinically important non‐fatal end point as defined by</b><a href="./references#CD011103-bbs2-0001" title="ShoresJ , BergerKR , MurphyEA , PyeritzRE . Progression of aortic dilatation and the benefit of long term beta‐adrenergic blockade in Marfan's syndrome. New England Journal of Medicine1994;330(9):1335‐41. ">Shores 1994</a><b>(</b>aortic dissection, aortic regurgitation, congestive heart failure, or cardiovascular surgery) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>316 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>249 per 1000</b> </p> <p>(117 to 534)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.79</b> </p> <p>(0.37 to 1.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> L<b>ow<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute aortic dissection</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>105 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> <p>(13 to 319)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.59</b> </p> <p>(0.12 to 3.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> L<b>ow<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aortic regurgitation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b> </p> <p>(9 to 419)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19</b> </p> <p>(0.18 to 7.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> L<b>ow<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Congestive heart failure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b> </p> <p>(9 to 419)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19</b> </p> <p>(0.18 to 7.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> L<b>ow<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular surgery</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>105 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> <p>(13 to 319)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.59</b> </p> <p>(0.12 to 3.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> L<b>ow<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Aortic root diameter &gt; 6 cm</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> </p> <p>(2 to 480)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19</b> </p> <p>(0.08 to 18.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> L<b>ow<sup>1,2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one step for risk of bias (high risk of selection, performance, detection, attrition and selective outcome reporting bias).<br/> <sup>2</sup>Downgraded one step for very serious imprecision (wide confidence interval with very low event rate). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Beta‐blockers compared with placebo, no treatment or surveillance only for preventing aortic dissection in Marfan's syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/full#CD011103-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011103-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Initial aortic diameter and ratio reported at baseline</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Initial aortic diameter</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Control male (N = 19)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Control female (N = 19)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Treatment male (N = 20)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Treatment female (N = 12)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measured (mm) ± SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.1 ± 6.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.4 ± 6.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.7 ± 9.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.2 ± 5.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Expected (mm) ± SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.6 ± 3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.3 ± 3.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.5 ± 4.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.3 ± 4.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ratio</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 ± 0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 ± 0.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.43 ±0.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.37 ± 0.2</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>SD: standard deviation</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Initial aortic diameter and ratio reported at baseline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/full#CD011103-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011103-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Blood pressure measured at baseline and during optimal dose</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> BP measured as mmHg ±SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Control male (N = 19)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Control female (N = 19)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Treatment male (N = 20)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Treatment female (N = 12)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SBP at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>118 ± 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110 ± 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115 ± 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115 ± 14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DBP at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72 ± 11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 ± 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73 ± 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69 ± 13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SBP during optimal dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108 ± 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108 ± 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DBP during optimal dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66 ± 11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63 ± 7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>BP: blood pressure; DBP: diastolic blood pressure; SBP: systolic blood pressure</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Blood pressure measured at baseline and during optimal dose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/full#CD011103-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011103-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse effects of long‐term treatment for 30 participants complying with beta‐blocker therapy</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Adverse effect</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Beta‐blocker group (N = 30)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Third‐degree heart block</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p>Not reported in <a href="./references#CD011103-bbs2-0001" title="ShoresJ , BergerKR , MurphyEA , PyeritzRE . Progression of aortic dilatation and the benefit of long term beta‐adrenergic blockade in Marfan's syndrome. New England Journal of Medicine1994;330(9):1335‐41. ">Shores 1994</a>, however, the study author reported that no adverse events </p> <p>occurred in the control group (personal communication)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐degree heart block</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lethargy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomina</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dream disturbance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild bronchospasm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Accentuated effects of alcohol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total with one or more effects</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>10</b> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse effects of long‐term treatment for 30 participants complying with beta‐blocker therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/full#CD011103-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011103-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Additional retrospective and prospective studies evaluating beta‐blocker therapy versus no treatment</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study design</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Results</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Conclusions</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0030" title="LadouceurM , FermanianC , LupoglazoffJM , EdouardT , DulacY , AcarP , et al. Effect of beta blockade on ascending aortic dilatation in children with the Marfan syndrome. American Journal of Cardiology2007;99:406‐9. ">Ladouceur 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0009"> <li> <p>Retrospective, multicentre study evaluating the evolution of aortic diameter in children with Marfan syndrome, receiving beta‐blocker initiated before 12 years of age (N = 77) compared to no treatment (N = 78) </p> </li> <li> <p>Beta blockers: atenolol (70%), nadolol (17%) and propranolol (6%)</p> </li> <li> <p>Treatment was initiated according to physician's practice: at diagnosis or documentation of aortic root dilatation. </p> </li> <li> <p>Aortic diameters were measured annually by echocardiography</p> </li> <li> <p>Follow up: &lt; 5 years</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0010"> <li> <p>155 children (82 boys, 73 girls) from 3 outpatient clinics in France</p> </li> <li> <p>&lt; 12 years at diagnosis</p> </li> <li> <p>Mean age at diagnosis in years: 6.1 ± 3.2 (treatment), 7.4 ± 5.2 (no treatment)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0011"> <li> <p>2 study groups were similar in age, height, weight, BP and heart rate at the time of diagnosis </p> </li> <li> <p>Aortic root dilatation was more frequent in the treatment group.</p> </li> <li> <p>Beta‐blocker therapy was started at an average of 1.3 years after diagnosis in the treatment group (mean age 7.5 ± 3.2 years). </p> </li> <li> <p>4 participants died in total (3 sudden deaths, 1 respiratory distress): 3 were from the control group </p> </li> <li> <p>2 of 77 children taking beta‐blockers stopped treatment during the study</p> </li> <li> <p>Adverse effects were not reported</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0012"> <li> <p>Beta‐blockade significantly decreased the rate of aortic dilatation by a mean of 0.16 mm/year compared with untreated participants (P = 0.0383) </p> </li> <li> <p>Very few mortality and morbidity events prevent further interpretation regarding the potential for harm. </p> </li> <li> <p>The study authors recommend treatment as soon as the diagnosis is made</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0032" title="LeggetME , UngerTA , O'SullivanCK , ZwinkTR , BennettRL , ByersPH , et al. Aortic root complications in Marfan's syndrome: identification of a lower risk group. Heart1996;75:389‐95. ">Legget 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0013"> <li> <p>Purpose of this study was to examine clinical and echocardiographic predictors of outcome in Marfan syndrome (N = 83) </p> </li> <li> <p>Follow‐up: mean = 4 years, range = &lt; 1‐16 years</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0014"> <li> <p>36% participants received beta‐blocker treatment for &gt; 1 year, 64% never received or received for &lt; 1 year </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0015"> <li> <p>Aortic ratios and the change in ratio between initial and final echocardiograms did not differ between the beta‐blocker and no‐beta‐blocker groups </p> </li> <li> <p>58 participants on beta‐blocker treatment reached a clinical event (defined as death or surgery for ascending aortic dissection or aneurysm) while 37 did not. Those who reached an event were on beta‐blocker therapy for a mean of 40 months compared to 20 months in those who didn't have a clinical event. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0016"> <li> <p>Actuarial freedom from all events was no different in those receiving beta‐blockers compared with those not receiving beta‐blockers at 5 years </p> </li> <li> <p>The study authors state the limitations of their study make interpretation of the data pertaining to beta‐blocker treatment difficult. </p> </li> <li> <p>A low‐risk subgroup of people with Marfan syndrome can be identified as those with aortic ratio &lt; 1.3 and annual change in aortic ratio &lt; 5% </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0042" title="PhomakayV , HuettWG , GossettJM , TangX , BornemeierRA , CollinsRT . β‐Blockers and angiotensin converting enzyme inhibitors: comparison of effects on aortic growth in pediatric patients with Marfan syndrome. Journal of Pediatrics2014;165:951‐5. ">Phomakay 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0017"> <li> <p>Retrospective, single‐centre study comparing the effect of beta‐blockers vs ACE‐inhibitors vs no treatment on aortic root growth rate in people with Marfan syndrome. A normal control group was also included. </p> </li> <li> <p>Pharmacological choice was provider‐dependent and initiated based on aortic measurements or accelerated dilatation. </p> </li> <li> <p>Beta blockers: atenolol (45.9%), metoprolol (48.5%), propranolol (5.6%)</p> </li> <li> <p>ACEI: daily lisinopril (12.9%), enalapril (85.5%), captopril (1.6%)</p> </li> <li> <p>Aortic measurements performed by echocardiography</p> </li> <li> <p>Mean follow‐up: 7.6 ± 5.8 years</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0018"> <li> <p>67 participants with confirmed Marfan syndrome (34 female, 33 male)</p> </li> <li> <p>Mean age at first encounter: 13 ± 10 years</p> </li> <li> <p>Mean age for untreated group: 9.8 years, beta‐blocker therapy: 16.9 years, ACEI: 16.8 years </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0019"> <li> <p>Beta‐blocker group had significantly lower heart rate but no difference in BP compared to untreated group. </p> </li> <li> <p>ACE inhibitor group had significantly higher BP compared to beta‐blocker and untreated group. The heart rate was lower compared to the untreated group, but no difference compared to the beta‐blocker group. </p> </li> <li> <p>AGV was significantly attenuated in the beta‐blocker group.</p> </li> <li> <p>Total of 1 participant died; study group not specified</p> </li> <li> <p>Total of 14 participants underwent surgeries (aortic root replacement in 11/14; median age 17 years). </p> </li> <li> <p>2 participants experienced aortic dissections: 1 from the beta‐blocker group, 1 from ACEI group </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0020"> <li> <p>Beta‐blocker therapy resulted in near normalisation of AGV</p> </li> <li> <p>ACEI did not significantly decrease AGV</p> </li> <li> <p>The study authors suggest early introduction of beta‐blocker therapy should be considered even prior to the demonstration of aortic dilatation. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0051" title="Rossi‐FoulkesR , RomanMJ , RosenSE , Kramer‐FoxR , EhlersKH , O'LoughlinJE , et al. Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome. American Journal of Cardiology1999;83:1364‐68. ">Rossi‐Foulkes 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0021"> <li> <p>Prospective, non‐randomised, non‐blinded study.</p> </li> <li> <p>Treatment (N = 27): beta‐blockers in most participants, verapamil in 1 Verapamil with asthma </p> </li> <li> <p>No treatment (N = 15)</p> </li> <li> <p>Dosage was adjusted to achieve maximally tolerated decrease in heart rate and BP</p> </li> <li> <p>Aortic measurements by echocardiography</p> </li> <li> <p>Follow‐up: 44 ± 24 months</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0022"> <li> <p>43 children (28 boys, 25 girls) with Marfan syndrome</p> </li> <li> <p>11 participants from non‐treatment group crossed over to the treatment group</p> </li> <li> <p>Average age at initial evaluation: 9.4 ± 5.3 years). Range 0.5‐17.8 years</p> </li> <li> <p>No treatment group: either none was recommended, or parental/participant refusal</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0023"> <li> <p>No significant difference in age, body size, BP, ocular, skeletal, cardiovascular abnormalities between male and female participants at baseline </p> </li> <li> <p>Aortic root dilatation was present in 79% of participants at initial evaluation</p> </li> <li> <p>Treated (beta‐blocker and calcium channel blocker) participants had slower aortic growth than untreated participants </p> </li> <li> <p>Major cardiovascular complications developed in 5 participants despite long‐term pharmacologic therapy: mitral regurgitation and aortic regurgitation, distal aortic dissection, and cardiovascular surgery </p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0024"> <li> <p>The study reports a beneficial impact of drug therapy on the absolute and relative rates of aortic root growth in children with Marfan syndrome </p> </li> <li> <p>The study authors report however, all aortic complications occurred in participants on long‐term therapy and therefore improved survival may be more fundamentally related to improved detection and appropriately timed surgical intervention. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0053" title="SalimMA , AlpertBS , WardJC , PyeritzRE . Effect of beta‐adrenergic blockade on aortic root rate of dilation in the Marfan syndrome. American Journal of Cardiology1994;74:629‐33. ">Salim 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0025"> <li> <p>Retrospective, non‐randomised study comparing beta‐blocker (N = 100) vs no treatment (N = 13) </p> </li> <li> <p>Beta‐blocker dose was achieved on basis of exercise challenge</p> </li> <li> <p>Beta blockers: propranolol and atenolol</p> </li> <li> <p>Aortic root diameter measured by Echocardiogram, CT or MRI</p> </li> <li> <p>Follow‐up: approximate range: 2‐8 years</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0026"> <li> <p>113 participants at 2 centres</p> </li> <li> <p>Control group: those who couldn't or wouldn't take beta‐blocker therapy</p> </li> <li> <p>Age &lt; 21 years at initial visit</p> </li> <li> <p>Mean age (years): control 10.2 ± 4.6, treatment: 14.1 ± 3.4 in 1 centre, 10.4 ± 3.4 in the other centre </p> </li> <li> <p>Heart rate and BP were used as measures of dosing and treatment efficacy</p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0027"> <li> <p>Mean aortic root diameter ≥ 95th percentile for the normal population</p> </li> <li> <p>Mean aortic root diameter was similar among groups at baseline</p> </li> <li> <p>Mean aortic diameter was significantly larger in the control group</p> </li> <li> <p>5 participants from the treated group required aortic valve replacement.</p> </li> <li> <p>Initial and final aortic root diameters in the surgical‐treated group was significantly larger than in remaining participants in the treated group </p> </li> <li> <p>Rapid increase in aortic root diameter during prepubertal and early pubertal years with maximal rate of increase during years 6‐14 </p> </li> </ul> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0028"> <li> <p>Greatest rate of aortic root dilatation was observed in the group that didn't receive any therapy </p> </li> <li> <p>The study authors recommend that participants with Marfan syndrome should begin beta‐blocker at the earliest age possible with the dose titrated to the largest dose tolerated. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0054" title="Selamet TierneyES , FeingoldB , PrintzBF , ParkSC , GrahamD , KleinmanCS , et al. Beta‐blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome. Journal of Pediatrics2007;150:77‐82. ">Selamet Tierney 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0029"> <li> <p>Retrospective, multicentre study evaluating the rate of aortic dilatation in children with Marfan syndrome prescribed beta‐blockade therapy (N = 29) compared to no treatment (N = 34) </p> </li> <li> <p>Atenolol dose titrated to goal dose of 25 mg in children, 50 mg in adolescents</p> </li> <li> <p>Aortic diameters were measured by echocardiography at 18‐month to 3‐year intervals</p> </li> <li> <p>Follow‐up: 81 months in control group, 76 months in treated group</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0030"> <li> <p>63 participants with Marfan syndrome from 2 centres</p> </li> <li> <p>Age: ≤ 18 years</p> </li> <li> <p>Mean age: control v treatment: 9.2 v 8.8 years</p> </li> <li> <p>Baseline: both groups well matched for mean age, weight, height, body surface area, sex, heart rate and heart rate z‐score </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD011103-list-0031"> <li> <p>No significant difference in aortic root measurements at baseline or study end between the treatment and control groups. </p> </li> <li> <p>1 death in total from the control group: died peri‐operatively during aortic valve replacement </p> </li> <li> <p>3 participants in total underwent aortic root replacement: 1 participant in the treatment group had intervention after aortic dissection. 2 control participants underwent elective intervention) </p> </li> <li> <p>Side effects documented in 35% of the treatment group</p> </li> <li> <p>Similar symptoms reported in 21% of the untreated group</p> </li> <li> <p>Specific exercise testing to assess adequacy of beta‐blockade not routinely performed, but heart rate and heart rate z‐scores were lower in the treatment group. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0032"> <li> <p>Beta‐blocker therapy does not significantly alter the rate of aortic root dilatation in children with Marfan syndrome. </p> </li> <li> <p>Similar number of participants from both study groups reached clinical endpoints</p> </li> <li> <p>The authors recommend that life‐time beta‐blocker therapy during childhood be reconsidered given their study findings, the potential for side effects and the lack of favourable late outcome data. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0055" title="SilvermanDI , BurtonKJ , GrayJ , BosnerMS , KouchoukosNT , RomanMJ , et al. Life expectancy in the Marfan syndrome. American Journal of Cardiology1995;75(2):157‐60. ">Silverman 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0033"> <li> <p>Large retrospective study with primary goal to evaluate life‐expectancy in Marfan syndrome </p> </li> <li> <p>Beta‐blockers: propranolol, atenolol, metoprolol and nadolol</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0034"> <li> <p>419 participants with Marfan syndrome from 4 centres</p> </li> <li> <p>119 participants were on beta‐blocker therapy</p> </li> <li> <p>Mean age when beta‐blockade therapy was begun: 28 ± 14 years</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0035"> <li> <p>Mean age for living members of the treated group was 33 ± 14 years compared to 31 ± 17 years in those who had never received beta blockers (P = 0.29) </p> </li> <li> <p>Median cumulate probability in beta‐blocker group was 72 years, compared to 70 years with no treatment (P = 0.01) </p> </li> <li> <p>Of the 47 participants that died, 8 were taking beta‐blockers.</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0036"> <li> <p>Life expectancy for participants increased by &gt; 25%, due to an overall improved population life expectancy, benefits of cardiovascular surgery, and increased frequency of diagnosis. </p> </li> <li> <p>Study authors state that their study design doesn't permit direct assessment of beta‐blockade on survival, however, their data suggest that medical therapy with beta‐blocker confers benefit in survival. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0057" title="TaherniaAD . Cardiovascular anomalies in Marfan's syndrome: the role of echocardiography and b‐blockers. Southern Medical Journal1993;86:305‐10. ">Tahernia 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0037"> <li> <p>Prospective study assessing beta‐blocker therapy versus no treatment in 6 people with Marfan syndrome </p> </li> <li> <p>Aortic dimensions measured by echocardiography annually</p> </li> <li> <p>Propranolol 15 mg twice a day</p> </li> <li> <p>Follow‐up: 2‐5 years</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0038"> <li> <p>6 participants (3 on propranolol, 3 controls)</p> </li> <li> <p>Mean age at beginning of study: 10 years in the study group, 9 years in the control group </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0039"> <li> <p>Control group had mild‐moderate aortic dilatation, treatment group had moderate‐severe aortic dilatation </p> </li> <li> <p>3 participants on beta‐blocker: no further dilatation of the aortic annulus diameter and ascending aorta. No side effects were reported </p> </li> <li> <p>3 participants on no treatment: evidence of progressive dilatation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0040"> <li> <p>After 2‐5 years of follow‐up, no progressive aortic dilatation was seen in any of the participants receiving low‐dose beta‐blockers </p> </li> </ul> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>ACEI: angiotensin‐converting enzyme inhibitor; AGV: aortic growth velocity; BP: blood pressure; CT: computerised tomography; MRI: magnetic resonance imaging </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Additional retrospective and prospective studies evaluating beta‐blocker therapy versus no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/full#CD011103-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011103-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Additional retrospective and prospective studies evaluating beta‐blocker therapy versus other anti‐hypertensive treatment</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study design</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patient population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conclusions</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0002" title="BhattAB , BuckJS , ZuflachtJP , MilianJ , KadivarS , GuavreauK , et al. Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome. Vascular Medicine2015;20:317‐25. ">Bhatt 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0041"> <li> <p>Randomised, double‐blind, parallel trial of losartan vs atenolol comparing their effects on arterial stiffness and left ventricular function in adults with Marfan syndrome </p> </li> <li> <p>Losartan 100 mg 1/day</p> </li> <li> <p>Atenolol 50 mg 1/day</p> </li> <li> <p>Follow‐up: 6 months</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0042"> <li> <p>34 participants</p> </li> <li> <p>Age: &gt; 18 years</p> </li> <li> <p>Atenolol; N = 17</p> </li> <li> <p>Losartan; N = 17</p> </li> <li> <p>Mean age in losartan group: 36 years, atenolol group: 34 years</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0043"> <li> <p>2 study groups were similar in all pre‐treatment variables (age, gender, heart rate, BP, cardiac and aortic measurements) </p> </li> <li> <p>Atenolol decreased pulse wave velocity significantly compared to losartan. However, this improvement was attenuated when adjusted for change in heart rate. </p> </li> <li> <p>Losartan decreased central augmentation pressure significantly compared to atenolol</p> </li> <li> <p>No significant change in aortic root or ascending aortic diameter between the 2 study groups </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0044"> <li> <p>Both atenolol and losartan favourably affected aortic stiffness in adults with Marfan syndrome </p> </li> <li> <p>Different mechanisms on improving aortic functional properties are implicated</p> </li> <li> <p>Study authors suggest a role for both beta‐blockers and ARBs in the treatment of Marfan syndrome. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0003" title="FortezaA , EvangelistaA , SanchezV , Teixido‐TuraG , SanzP , GutierrezL , et al. Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial. European Heart Journal2016;37:978‐85. ">Forteza 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0045"> <li> <p>Phase IIIb, randomised, parallel, double‐blind study to determine the efficacy of losartan (N = 70) or atenolol (N = 70) in Marfan syndrome </p> </li> <li> <p>Follow‐up: 3 years</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0046"> <li> <p>140 participants from 2 clinical centres</p> </li> <li> <p>Mean age: range 5‐60 years</p> </li> <li> <p>Inclusion criteria: aortic root diameter &lt; 45 mm</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0047"> <li> <p>No serious drug‐related adverse effects observed</p> </li> <li> <p>Aortic root diameter increased significantly in both groups</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0048"> <li> <p>There was no significant difference in progression of aortic root and ascending aortic diameters between losartan and atenolol in participants with Marfan syndrome </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0004" title="LacroRV , DietzHC , SleeperLA , YetmanAT , BradleyTJ , ColanSD , et al. Atenolol versus losartan in children and young adults with Marfan's syndrome. New England Journal of Medicine2014;371:2061‐71. ">Lacro 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0049"> <li> <p>Randomised, multicentre trial comparing losartan (N = 305) with atenolol (N = 303) in children and young adults with Marfan syndrome </p> </li> <li> <p>Atenolol was increased on the basis of haemodynamic response to a maximum dose of 4 mg/kg daily </p> </li> <li> <p>Losartan was adjusted on the basis of body weight to a maximum dose of 1.4 mg/kg daily</p> </li> <li> <p>Aortic measurements performed by echocardiography every study visit, 6‐12 months apart</p> </li> <li> <p>Follow‐up: 3 years</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0050"> <li> <p>604 participants from 21 clinical centres</p> </li> <li> <p>Mean age: 11.5 in atenolol group, 11.0 in losartan. Range: 6 months‐25 years</p> </li> <li> <p>Aortic‐root z‐score was &gt; 3.0 in both groups</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0051"> <li> <p>Similar baseline clinical and echocardiographic characteristic between groups</p> </li> <li> <p>There was no significant difference in baseline‐adjusted rate of change in aortic‐root z‐score between the 2 study groups </p> </li> <li> <p>Small but significant difference in favour of atenolol in absolute diameter and z‐score for aortic annulus </p> </li> <li> <p>Both study groups indicated a decrease in the degree of aortic‐root dilatation relative to body‐surface area </p> </li> <li> <p>Younger age at baseline was associated with greater decrease in aortic‐root z‐score over time in both groups </p> </li> <li> <p>Diastolic BP was slightly lower in the atenolol group, but there were no differences in systolic or mean BPs </p> </li> <li> <p>Heart rate was significantly lower in the atenolol group</p> </li> <li> <p>There was no significant difference in 3 years in the rates of adverse clinical outcomes (aortic root surgery, aortic dissection, death) </p> </li> <li> <p>Rate of adverse events possibly higher in atenolol group, but no significant difference in serious adverse events </p> </li> <li> <p>No significant difference in withdrawal rate (11% per group) or median time to withdrawal.</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0052"> <li> <p>No significant difference in the rate of aortic root dilatation between the losartan and beta‐blocker therapy group among children and young adults with Marfan syndrome </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0005" title="SandorGGS , AlghamdiMH , RagginLA , PottsMT , WilliamsLD , PottsJE , et al. A randomized, double blind pilot study to assess the effects of losartan vs atenolol on the biophysical properties of the aorta in patients with Marfan and Loeys‐Dietz syndromes. International Journal of Cardiology2015;179:470‐5. ">Sandor 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0053"> <li> <p>Randomised, double‐blind. pilot study assessing the effects of losartan v atenolol on the biophysical properties of the aorta in Marfan and Loeys‐Dietz syndromes (LDS) </p> </li> <li> <p>Atenolol: 25 mg‐50 mg, losartan 25 mg daily</p> </li> <li> <p>Aortic dimensions measured by echocardiography prior to and after therapy</p> </li> <li> <p>Follow‐up: 12 months</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0054"> <li> <p>All 17 eligible participants were diagnosed with Marfan syndrome, 1 tested positive for both Marfan syndrome and LDS </p> </li> <li> <p>Atenolol group: 9 women</p> </li> <li> <p>Losartan group: 7 men, 1 woman</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0055"> <li> <p>Baseline height, weight, body surface area, body mass and BP were similar. There was a significant gender difference. </p> </li> <li> <p>No significant aortic root dilatations occurred during the trial.</p> </li> <li> <p>There was no significant difference for losartan to decrease pulse wave velocity and stiffness index </p> </li> <li> <p>There was no significant difference for atenolol to improve hydraulic power</p> </li> <li> <p>There was no decrease in contractility by atenolol</p> </li> <li> <p>Adverse effects were not reported</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0056"> <li> <p>Study authors cannot draw definite conclusions due to limitations of the study, but suggest atenolol and losartan have different mechanisms of action on vascular function </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0006" title="WilliamsA , KennyD , WilsonD , FagenelloG , NelsonM , DunstanF , et al. Effects of atenolol, perindopril and verapamil on haemodynamic and vascular function in Marfan syndrome ‐ a randomised, double‐blind, crossover trial. European Journal of Clinical Investigation2012;42(8):891‐99. ">Williams 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0057"> <li> <p>Randomised, double‐blind cross‐over trial assessing the effects of atenolol, perindopril and verapamil on haemodynamic and vascular function in Marfan syndrome </p> </li> <li> <p>Atenolol: 75 mg</p> </li> <li> <p>Perindopril 4 mg</p> </li> <li> <p>Verapamil 240 mg</p> </li> <li> <p>Echocardiographic measurements</p> </li> <li> <p>Follow‐up: 18 weeks</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0058"> <li> <p>18 participants from 2 tertiary congenital heart disease centres</p> </li> <li> <p>Mean age: 30.4 ± 11.7</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0059"> <li> <p>Aortic root dimensions &lt; 5 cm at study baseline</p> </li> <li> <p>All drug groups reduced central systolic BP and brachial pressure.</p> </li> <li> <p>Atenolol reduced heart rate and delayed aortic wave travel</p> </li> <li> <p>No‐drug group altered the pulse wave velocity</p> </li> <li> <p>No significant change in aortic root diameter between groups and between baseline and study endpoint </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0060"> <li> <p>All drug groups reduced peripheral and central systolic BP</p> </li> <li> <p>Study authors suggest beta‐blockers have a continuing role in the treatment of Marfan syndrome </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011103-bbs2-0065" title="YetmanAT , BornemeierRA , McCrindleBW . Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. American Journal of Cardiology2005;95:1125‐7. ">Yetman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0061"> <li> <p>Prospective, non‐randomised trial assessing the effects of enalapril vs beta‐blocker therapy in people with Marfan syndrome </p> </li> <li> <p>Beta‐blocker: propranolol or atenolol depending on participant weight. Dose titrated to maximum of 2 mg/kg daily for atenolol, 1 mg/kg twice daily for propranolol </p> </li> <li> <p>ACEI: enalapril. Titrated to maximum dose of 10 mg twice daily</p> </li> <li> <p>Doses adjusted according to adverse effects experienced by participant, not haemodynamic effects </p> </li> <li> <p>Bi‐annual echo‐cardiographic assessment</p> </li> <li> <p>Follow‐up: 3.0 ± 0.2 years</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0062"> <li> <p>57 participants: 32 enalapril, 24 atenolol, 2 propranolol</p> </li> <li> <p>Mean age at start of therapy (years): 12.8 ± 7.8</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0063"> <li> <p>Improved aortic distensibility and a reduced aortic stiffness index in participants receiving enalapril and subsequently associated with a slower rate of aortic growth </p> </li> <li> <p>6 participants from beta‐blocker group discontinued treatment due to adverse effects (depression, fatigue, short‐term memory loss), and subsequently enrolled to enalapril group </p> </li> <li> <p>1 death from beta‐blocker treatment group (documented ventricular tachyarrhythmia); no evidence of aortic dissection </p> </li> <li> <p>9 participants had aortic root replacement (2 from enalapril, 7 from the beta‐blocker group) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD011103-list-0064"> <li> <p>ACEI provide therapeutic benefit in adults with Marfan syndrome compared to beta‐blocker treatment </p> </li> </ul> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>ACEI: ACEI: angiotensin‐converting enzyme inhibitor; ARB: angiotensin receptor blockers; BP: blood pressure </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Additional retrospective and prospective studies evaluating beta‐blocker therapy versus other anti‐hypertensive treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/full#CD011103-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011103-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Beta‐blocker versus no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.01, 4.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinically important non‐fatal endpoints as defined by Shores 1994 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.37, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Acute aortic dissection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.12, 3.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Aortic regurgitation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.18, 7.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Congestive heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.18, 7.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Cardiovascular surgery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.12, 3.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Aortic root diameter &gt; 6 cm <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.08, 18.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Beta‐blocker versus no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011103.pub2/references#CD011103-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011103.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011103-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011103-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD011103-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD011103-note-0002">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011103-note-0011">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011103\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011103\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011103\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011103\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011103\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011103\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011103\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011103\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011103\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011103\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011103\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011103\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011103\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011103\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011103\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011103\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011103\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011103\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=4nUWI3Cc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011103.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011103.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011103.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011103.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011103.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718030592"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011103.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718030596"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011103.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dc6619f4af49c',t:'MTc0MDcxODAzMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 